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Как хорошо! вот сладкий плод ученья! 
Как с облаков ты можешь обозреть 
Всё царство вдруг: границы, грады, реки. 
Учись, мой сын: наука сокращает 
Нам опыты быстротекущей жизни — 
Когда-нибудь, и скоро, может быть, 
Все области, которые ты ныне 
Изобразил так хитро на бумаге, 
Все под руку достанутся твою — 
Учись, мой сын, и легче и яснее 
Державный труд ты будешь постигать. 
 
(“Борис Годунов”, 1831, А.С.Пушкин) 
Very good! Here's the sweet fruit  
Of learning. One can view as from the clouds 
Our whole dominion at a glance; its frontiers, 
Its towns, its rivers. Learn, my son; 'tis science 
Which gives to us an abstract of the events 
Of our swift-flowing life. Some day, perchance 
Soon, all the lands which thou so cunningly 
Today hast drawn on paper, all will come 
Under thy hand. Learn, therefore; and more smoothly, 
More clearly wilt thou take, my son, upon thee 
The cares of state. 
 
(“Boris Godunov”, 1831, A.S. Pushkin) 
 
 
 
 
 
To my family 
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ABSTRACT 
Neurotrophic factors are small secretory proteins with essential roles in neuronal and non-
neuronal tissues. Mesencephalic astrocyte-derived neurotrophic factor (MANF) and cerebral 
dopamine neurotrophic factor (CDNF) form a distinct family of unconventional neurotrophic 
factors. MANF and CDNF are endoplasmic reticulum (ER) located, but also secreted 
proteins. Initially, MANF was discovered as a trophic factor for dopamine neurons in vitro. 
Further studies revealed its protective and restorative properties in different animal disease 
models such as Parkinson´s disease, spinocerebellar ataxia, brain- and heart-ischemia. 
MANF is also identified as a protein upregulated in unfolded protein response (UPR) and 
protecting against ER stress-induced cell death. CDNF was identified based on its homology 
to MANF and characterized for its ability to protect and restore dopamine neurons in rodent 
models of Parkinson´s disease. However, the physiological roles of MANF and CDNF in 
mammals have remained unclear. The main objective of this thesis was, therefore, to study 
the biological roles of MANF in vivo by characterizing the phenotypes of MANF 
conventional and conditional knockout mice as well as analyzing MANF and CDNF 
expression in mouse tissues. 
Comprehensive expression analysis of MANF mRNA and protein revealed that MANF 
is widely expressed in most mouse tissues. It is highly expressed in neurons regulating energy 
homeostasis within the hypothalamus and neurons of other appetite-regulating areas 
including the brainstem structures and mesolimbic/mesocortical dopamine system. 
Exceptionally high levels of MANF was observed on peripheral mouse tissues with 
metabolic function, especially in cells with secretory functions within the endocrine and 
exocrine glands, suggesting essential roles for MANF in cells with high protein synthesis and 
secretion. Highest levels of CDNF protein was observed in tissues with high energy 
production and oxidative function including skeletal muscle, heart, testis and brown adipose 
tissue.  
Silencing of a gene by genetic modifications can give insights on its biological functions 
in vivo in animals. Conventional knockout, as well as conditional knockout mouse models, 
are valuable tools to discover the roles of a gene in embryonic development and normal 
physiological homeostasis. In order to study the roles of MANF in mammals, we deloped 
MANF conventional knockout mice (Manf-/-), that showed severe growth retardation, poor 
survival and a progressive postnatal reduction of beta-cell mass resulting in severe insulin-
deficient hyperglycemia and diabetes mellitus caused by decreased beta-cell proliferation and 
increased beta-cell apoptosis. In our further studies, we verified that diabetic phenotype of 
the Manf-/- mice was caused by a lack of MANF in the insulin-producing beta-cells in the 
pancreas and not in other organs by generating pancreas- and beta-cell-specific conditional 
Manf-/- mice. Our results show that embryonic ablation of MANF in the pancreases of mice 
and ablation of MANF from beta-cells of adult mice resulted in diabetes. We found that 
pancreatic islets of conventional and conditional MANF deficient mice displayed chronic 
activation of the UPR, preceding downregulation of beta-cell markers, indicating unresolved 
ER stress as one possible cause of beta-cell failure in these mice. Thus, this work shows that 
MANF is an essential regulator of beta-cell maintenance and UPR in mice. 
ii 
Diabetes mellitus (DM) is characterized by hyperglycemia and deficient insulin 
production that is associated with pancreatic beta-cell deficiency and/or dysfunction and 
leads to massive morbidity and mortality. According to the International Diabetes Foundation 
(2017), the incidence of diabetes is rising worldwide, and DM will affect 629 million people 
worldwide by 2045. Most common types of DM are type 1 diabetes (T1D) and type 2 diabetes 
(T2D). In the case of T1D, the reduction of insulin secretion is caused by the progressive 
autoimmune destruction of pancreatic beta-cells. T2D is associated with insulin resistance in 
the peripheral target tissues, followed by the beta-cell dysfunction and loss of pancreatic beta-
cell mass. Current technologies for DM treatment do not prevent disease progression, which 
typically results in devastating long-term diabetic complications. Therefore, new therapies 
directed for protection pancreatic beta-cell mass and function as well as rejuvenation of the 
remaining beta-cells are under intensive investigation. 
We discovered that MANF protein increased beta-cell proliferation in vitro in islets 
isolated from young and even old mice with very slow beta-cell turnover. MANF protein also 
rescued mouse beta-cells from thapsigargin-induced apoptosis and ER stress-induced 
glucotoxicity in culture. Importantly, we found that MANF overexpression in the mouse 
pancreases mediated by adeno-associated virus vector was able to regenerate beta-cells in 
vivo in a mild low-dose streptozotocin mouse model of diabetes. Hence, these results indicate 
that MANF is a vital mitogen and protective protein for mouse beta-cells and can thus serve 
as a potential new regenerative drug for the diabetes therapy.  
Furthermore, we identified the decreased number of growth hormone (GH) and prolactin 
(PRL) expressing cells in the anterior pituitary gland of Manf-/- knockout mice associated 
with increased expression of UPR markers and decreased expression of Gh and Prl genes. 
Thus, reduced GH production could be one of the reasons for the growth retardation in  
Manf-/- mice. These results identify indispensable roles for MANF also in endocrine cells of 
the anterior pituitary besides the pancreatic beta-cells in the Manf-/- mice. 
Taken together, the results in this thesis provide new critical biological functions of 
MANF in mouse in vivo which can be used to exploit the roles of MANF in human beta-cells 
and diabetes as well as in endocrine somatotropic cells and growth failure in human. 
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1 
REVIEW OF LITERATURE 
1.  Neurotrophic factors and growth factors 
Neurotrophic factors (NTFs) are small secretory proteins that during development and 
adulthood promote the survival of neurons, maintain their neuritic contacts and regulate 
neuronal plasticity. Outside the nervous system, NTFs have essential functions with 
therapeutic potential for the treatment of various chronic neurological and metabolic 
disorders. 
In the early 1950’s the first growth factors discovered by developmental biologist Rita 
Levi-Montalcini and biochemist Stanley Cohen were the nerve growth factor (NGF) and 
epidermal growth factor (EGF) respectively. Currently, there are four major NTF families: 
neurotrophins, the GDNF family ligands (GFLs), the neuropoietic cytokines, and the 
CDNF/MANF family. In addition to these families, various other growth factors families like 
transforming growth factor β (TGF β), vascular endothelial growth factor (VEGF), insulin-
like growth factors (IGF) and fibroblast growth factor (FGF) have neurotrophic activities  
(Grothe and Timmer, 2007; Zacchigna et al., 2008). 
Neurotrophin family is represented by NGF, brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4), signaling of which is critically important 
for the development and maintenance of the nervous system (Huang and Reichardt, 2001; Lu 
et al., 2005). Neurotrophin family members were shown to regulate energy homeostasis 
(Fargali et al., 2012). NGF and BDNF are also known to regulate the immune cell activity 
(Calabrese et al., 2014; Minnone et al., 2017). NT-3 and its high-affinity tropomyosin 
receptor kinase C (TrkC) regulate heart development by modulating the replication of 
embryonic cardiomyocytes (Donovan et al., 1996; Lin et al., 2000). Moreover, BDNF was 
shown to be involved in regulation of glucose metabolism in mice and humans with type 2 
diabetes (Tonra et al., 1999; Krabbe et al., 2007).  
The four members of the GFLs include GDNF, Neurturin (NRTN), Artemin (ARTN) 
and Persephin (PSPN). The GFLs play an essential role in the development, differentiation, 
and maintenance of various neurons (Airaksinen and Saarma, 2002). In addition, GDNF is 
important for kidney development and spermatogonial differentiation (Pichel et al., 1996; 
Meng et al., 2000). Moreover, recent studies identified protective and mitogenic functions of 
GDNF for pancreatic beta-cells (Mwangi et al., 2008). 
Mesencephalic astrocyte-derived neurotrophic factor (MANF) and cerebral dopamine 
neurotrophic factor (CDNF) are a diverse family of evolutionarily conserved neurotrophic 
factor family (Petrova et al., 2003; Lindholm et al., 2007; Palgi et al., 2009). MANF was 
initially purified from the of rat type-1 astrocyte ventral mesencephalic cell line 1 (VMCL1)  
culture medium and discovered its protective properties on embryonic dopaminergic neurons 
in vitro (Petrova et al., 2003). The second member of the trophic factor family, CDNF, was 
determined by a bioinformatics and biochemical analysis based on its homology to MANF 
(Lindholm et al. 2007). A single orthologue of mammalian MANF and CDNF was identified 
2 
in invertebrates including fruit fly, pea aphid and marine sponge and revealed about 50% 
identity with human MANF. 
1.1  Sequence and three-dimensional structure of MANF and CDNF 
MANF and CDNF are both 18 kDa secreted proteins, highly soluble and monomeric in 
neutral solution (Lindholm et al., 2007; Mizobuchi et al., 2007; Hoseki et al., 2010; Hellman 
et al., 2011; Latge et al., 2015). Sequence analysis revealed that human MANF and CDNF 
are 179 and 187 amino acid residues long, respectively.  
Both proteins contain a predicted signal sequence and biologically active mature region. 
The pre-region of MANF is 21 amino acids long, and the mature form of MANF contains 
158 amino acid residues (Petrova et al., 2003). CDNF, in turn, encodes 26 amino acids long 
signal sequence and 161 residues long mature region (Lindholm et al., 2007). Full-length 
human CDNF and MANF sequences are 59% amino-acid identical. Differently from other 
classical NTFs, CDNF and MANF lack the pro sequence, indicating that enzymatic cleavage 
is not required for their activation. Moreover, both MANF and CDNF have eight conserved 
cysteine residues that form four disulfide bridges, while neurotrophins and other GFLs have 
seven (Airaksinen and Saarma, 2002; Petrova et al., 2003; Lindholm et al., 2007).  
Several groups have studied the three-dimensional structure of MANF and CDNF using 
X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy in aqueous 
solution (Parkash et al., 2009; Hoseki et al., 2010; Hellman et al., 2011; Latge et al., 2015). 
Based on these studies, MANF and CDNF have a similar 3D structure. They contain two 
distinct domains connected with a short linear sequence. NMR studies of the full-length 
proteins confirmed the folding of MANF and CDNF into two domains linked with a flexible 
loop (Hellman et al., 2011; Latge et al., 2015). The 12 kDa N-terminal domain is structurally 
similar to saposin-like proteins (Parkash et al., 2009), a family of proteins with ability to 
interact with lipids (Bruhn, 2005). A recent study demonstrated that MANF but not CDNF 
bind to lipid sulfatides in the membrane of cell membranes of C. elegans and mammalian 
cells (Bai et al., 2018). Moreover, the ability of MANF to bind sulfatides was reduced by 
mutation at its N-terminal part, indicating that MANF directly binds sulfatides via its N-
terminal part. 
The 6 kDa C-terminal domain of MANF and CDNF resembles the SAP-like domain in 
Ku70, which is an inhibitor of the pro-apoptotic Bax protein (Hellman et al., 2011; Latge et 
al., 2015). The C-terminal MANF protected neurons against Bax-induced apoptosis in vitro 
efficiently as Ku70 (Hellman et al., 2011), although the mechanism was not studied. The 
SAP-like domain of MANF and CDNF might bind to DNA (Hellman et al., 2011).  
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Figure 1. (A) The schematic image represents a comparison of the human MANF and CDNF 
structures with that of GDNF. The N-terminal saposin-like and C-terminal SAP-like domains of 
MANF and CDNF are shown in blue and orange, respectively. Yellow bars are representing 
conserved cysteine residues according to the mature protein sequence. The formation of cysteine 
bridges is shown in black connecting lines and proposed disulfide bridges. Red bars are indicative of 
ER retention signal. Differently from MANF and CDNF, the primary structure of GDNF contains a 
pro sequence, indicating that enzymatic activation of pro-region is needed for its activation. Mature 
GDNF is represented in green and disulfide bonds modeling three disulfide bridges and a cysteine 
motif are marked with black lines. Two GDNF molecules form a covalently linked homodimer. 
Disulfide bridge and a cysteine residue implicated in this process are shown by an arrow. H.s.; Homo 
sapiens. (B) Crystal structure of human MANF containing of the N-terminal saposin-like domain and 
the C-terminal SAP-like domain. Alpha-helices (a) are marked from the beginning of the N-terminus. 
The area between residues 96–103 represents the linker region. CGKC loop motif, ER retention signal 
RTDL, N - amino-terminus, C, carboxy-terminus are marked on the scheme. The image is adapted 
from (Lindahl et al., 2017) 
Another study identified the interaction of C-terminal domain of MANF with the DNA-
binding subunit of NF-κB p65, although the exact binding mechanism was not addressed 
(Chen et al., 2015a). 
Conserved motifs of MANF and CDNF include four disulfide bridges and an ER 
retention signal at their C-terminal domains. Two cysteines in the conserved CXXC motif 
that can be found in the catalytic centers of redox enzymes, form one disulfide bridge. 
Although numerous attempts have failed to demonstrate the oxidoreductase activity of 
MANF (Mizobuchi et al., 2007; Hartley et al., 2013; Matlik et al., 2015), a mutational 
analysis of the CXXC motif did reveal that this motif is indispensable for the cytoprotective 
function of MANF (Lindstrom et al., 2013; Matlik et al., 2015). 
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Moreover, the last four amino acids of the C-terminal domain of MANF and CDNF, 
RTDL and KTEL respectively, resemble the KDEL ER retention signal that can mediate their 
binding to KDEL receptors and facilitate their ER retention (Raykhel et al., 2007). Both 
MANF and CDNF are intracellular proteins that predominantly reside within the ER 
(Apostolou et al., 2008; Tadimalla et al., 2008; Sun et al., 2011; Henderson et al., 2013; 
Fernandez et al., 2014; Matlik et al., 2015). Deletion of the RTDL motif from MANF 
sequence results in enhanced secretion of MANF and its mislocalization from the ER to Golgi 
both in cultured cells and neurons (Glembotski et al., 2012; Henderson et al., 2013; 
Henderson et al., 2014). Similarly, ablation of KTEL motif from CDNF resulted in the 
increased secretion of overexpressed CDNF (Norisada et al., 2016), indicating diminished 
ER retention. 
1.2  MANF and CDNF expression in the mouse and human tissues 
Analysis of MANF expression was addressed by different techniques, such as in situ 
hybridization (ISH), reverse transcription polymerase chain reaction (RT-PCR), Western 
blotting and immunohistochemistry (IHC) analyses (Lindholm et al., 2008; Wang et al., 
2014; Yang et al., 2014a; Tseng et al., 2017; Yang et al., 2017). During embryonic 
development, wide MANF expression was observed in the mouse CNS and peripheral tissues 
(Lindholm et al., 2008). High expression of MANF was detected in the dorsal root ganglia, 
trigeminal ganglia, and superior cervical ganglion by IHC. In non-neuronal tissues, high 
levels of MANF was identified in the pancreas, salivary gland, liver and the cartilage cells 
during embryo development. 
Broad expression of MANF protein and mRNA have been observed in mouse tissues 
postnatally. Within the rodent brain, MANF expression was mainly detected in the neuronal 
cells and not astrocytes by IHC (Lindholm et al., 2008; Tseng et al., 2017). ISH revealed 
Manf mRNA expression in different postnatal and adult rodent brain regions including 
olfactory bulb, cortex, hippocampus, hypothalamus, substantia nigra and spinal cord. MANF 
positive neurons were co-expressed with tyrosine hydroxylase (TH)-positive neurons in 
substantial nigra in both mouse and rat (Lindholm et al., 2008; Wang et al., 2014). 
Interestingly, MANF expression in the rat brain was the highest at two-weeks of age with 
decreasing levels thereafter (Wang et al., 2014). Moreover, MANF co-expressed with 
calbindin-positive Purkinje cells (Yang et al., 2014a).  
Outside the CNS, it was shown that MANF protein is broadly expressed in the non-
neuronal cells of adult mouse tissues. Especially MANF was strong in the secretory tissues 
such as pancreatic exocrine cells and endocrine islets of Langerhans, salivary gland and testis 
(Mizobuchi et al., 2007; Lindholm et al., 2008), indicating unique properties of MANF in the 
cells with high protein synthesis and secretion. 
Studies of MANF expression in the human tissues have not been extensive (Lindholm 
et al., 2008). MANF mRNA was detected in several human brain regions and human 
peripheral tissues similarly to mouse as previously reported by Lindholm et al (Lindholm et 
al., 2008). Recent findings revealed the presence of MANF in the human blood serum (Galli 
et al., 2016). 
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Previously Lindholm et al. demonstrated that Cdnf mRNA and protein levels in the 
mouse tissues had been shown to be generally lower than MANF levels (Lindholm et al., 
2007). Cdnf mRNA expression was detected in the mouse CNS as well as adult human brain 
studied. CDNF expression was observed in the mouse neurons of cortex, striatum, 
hippocampus, substantia nigra, locus coeruleus and Purkinje cells of the cerebellum. In 
contrast to MANF, no CDNF expression was observed in dopaminergic neurons of the 
substantia nigra. Additionally, authors detected CDNF mRNA in all analyzed non-neuronal 
tissues in human and mouse, where highest levels of CDNF were found in heart, muscle and 
testis (Lindholm et al., 2007).  
To conclude, both MANF and CDNF are ubiquitously expressed in mouse and human 
neuronal and non-neuronal tissues. However, the pattern and the levels of their expression 
differs from each other, indicating distinct functions of these homologous proteins.  
1.3  Functions of MANF 
1.3.1 MANF therapeutic potential in rodent models of Parkinson’s disease 
Parkinson’s disease (PD) is a neurodegenerative disease associated with specific loss of 
dopamine neurons in substantia nigra pars compacta and their projections to the caudate 
putamen (in rodents striatum) (Andressoo and Saarma, 2008). The motor symptoms of PD 
first appear when 40 to 50% of the dopamine neurons are lost and include rigidity, tremor, 
involuntary, and slowed movement (Lang and Lozano, 1998; Dauer and Przedborski, 2003). 
It remains unknown what is the primary cause of the dopamine neuron degeneration in PD. 
According to the current view PD is triggered by a combination of underlying genetic 
predisposition and environmental exposures. 
The 6-hydroxydopamine (6-OHDA) model of PD was the first established rodent model 
of PD, and has been extensively used to investigate Parkinsonism ever since 1968 (Simola et 
al., 2007). MANF was shown to protect and promote functional recovery of dopamine 
neurons in rodent PD models. Intrastriatal delivery of human recombinant MANF effectively 
protected dopamine neurons and improved locomotor behavior in 6-OHDA-induced rat 
model of PD (Voutilainen et al., 2009), although these results were not reproduced in a more 
severe 6-OHDA model when MANF was chronically infused (Voutilainen et al., 2011). 
Intrastriatal lentiviral delivery of MANF had no effect in a rat model of PD induced by the 
6-OHDA (Cordero-Llana et al., 2015), but the authors did not document MANF expression 
in the midbrain. Although intranigral delivery rescued dopamine neurons in substantia nigra 
pars compacta, it did not affect the TH-fiber density in striatum neither improved the 
behavioral deficit. However, MANF expression was not demonstrated.  Other studies 
identified that AAV9-mediated delivery of MANF to the striatum of rat brains protected the 
neurons from 6-OHDA (Hao et al., 2017). AAV9-MANF promoted recovery of the TH-
positive dopamine neurons in the substantia nigra, leading to increased TH-fiber density in 
the striatum and improved locomotor behavior.  
The mechanisms of protective action of MANF is unknown but current data points 
towards several possible mechanisms of action. Studies revealed that MANF rescued SH-
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SY5Y cells from the 6-OHDA induced apoptosis by inhibiting autophagy through the 
initiation of the AMPK/mTOR cascade (Zhang et al., 2017b). MANF-mediated protection 
against 6-OHDA-induced cytotoxicity was suggested to be regulated via the 
PI3K/Akt/GSK3β pathway by regulating the expression of nuclear factor erythroid 2-related 
factor (Nrf2) (Zhang et al., 2017c). Moreover, MANF protected SH-SY5Y cells from the 6-
OHDA induced apoptosis and overexpressed α-synuclein via upregulation of some ER stress 
markers  (Huang et al., 2016; Sun et al., 2017). In addition, the protective roles of viral vector 
delivered MANF on 6-OHDA treated cells corresponded with decreased unfolded protein 
response (UPR) (Hao et al., 2017). Taken together, although some mechanistic insights were 
proposed, the exact mode of MANF therapeutic action remains unclear. 
1.3.2 MANF therapeutic potential in a mouse model of spinocerebellar ataxia  
Spinocerebellar ataxia 17 (SCA17) is a neurodegenerative disease characterized by selective 
degeneration of the Purkinje cells in the cerebellum (Toyoshima et al., 1993). SCA17 is 
caused by a poly-glutamine expansion of the transcription factor of TATA-box binding 
protein (TBP). Decreased expression of MANF in the cerebellar Purkinje cells followed by 
their degeneration was observed in a conditional knock-in mouse of mutated TBP (Yang et 
al., 2014a). Degeneration of Purkinje cells was diminished by MANF overexpression via 
protein kinase C (PKC)-dependent signaling (Yang et al., 2014a), suggesting a protective 
role for MANF in Purkinje cells. To date, no other studies revealing MANF functions via 
PKC pathway are known. Moreover, MANF concentrations (1.5 mg/ml) used in this study 
are not physiological. Recent studies revealed that ER stress contributes to the pathogenesis 
of SCA17 and MANF suppresses ER stress consequently diminishing the mutant TBP 
toxicity (Guo et al., 2018), indicating that MANF exerts is beneficial effects through 
dampening ER stress.  
1.3.3 MANF roles in inflammation 
Inflammation is a major pathological event in many chronic and degenerative diseases (Chen 
et al., 2018). It is the response of the immune system to harmful stimuli, which helps to 
alleviate infections, initiates clearance of the damaged cells and pathogens, and repair of 
injured tissue (Medzhitov, 2010). These processes lead to the recovery of tissue homeostasis 
and the termination of the acute inflammation. However, if not resolved, acute inflammation 
becomes chronic (Nathan and Ding, 2010), contributing to a variety of chronic inflammatory 
diseases including auto-immune diabetes, cardiovascular diseases, atherosclerosis, 
rheumatoid arthritis, and cancer (Sugimoto et al., 2016). Inflammatory responses also occur 
in neurodegenerative diseases like PD, Alzheimer's diseases, stroke, and epilepsy (Chen et 
al., 2018). Chronic inflammation associated with aging disrupts metabolic function in 
mammals, leading to obesity and diabetes (Barzilai et al., 2012). Hence, there is a great need 
for developing new potential anti-inflammatory drugs.  
MANF has an essential role in the modulation of immune responses. It was documented 
that MANF expression is detected in immune cell of invertebrates and vertebrates, and its 
expression is upregulated upon inflammatory responses (Chen et al., 2015a; Liu et al., 2015a; 
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Neves et al., 2016; Sereno et al., 2017). MANF rescued astrocytes from oxygen-glucose 
deprivation (OGD) and promotes cell survival by reducing the expression and secretion of 
proinflammatory cytokines IL-1β, IL-6, and TNF-α induced by ER stress and detected after 
OGD (Zhao et al., 2013). Moreover, treatment with MANF led to decreased levels of GRP78 
and NF-κB p65 that are also induced by OGD.  Other studies identified that MANF 
suppresses the transcriptional activities of NF-κB inflammatory pathways in synoviocytes 
(Chen et al., 2015a). Moreover, MANF has been shown to promote anti-inflammatory 
activation of immune cells in both flies and mice. MANF expression promoted by PDGF-A 
in injured retina cells in flies and mice induced alternative activation of innate anti-
inflammatory M2-type immune cells, thereby promoting retinal tissue repair and enhancing 
the success of photoreceptor replacement therapies (Neves et al., 2016). Thus MANF seems 
to act as an anti-inflammatory agent by reducing ER stress and production of pro-
inflammatory cytokines and also by affecting alternative activation of anti-inflammatory 
immune cells. 
MANF expression was shown to decline with aging in flies, mouse tissues (liver, 
muscle, fat, and skin) and human skin (Sousa-Victor et al., 2019). Levels of MANF were 
reduced in both mouse and human serum with age. Silencing of MANF in fruit fly 
ubiquitously or specifically in immune cells (hemocytes) resulted in disrupted intestinal 
homeostasis, age-related activation of JAK/STAT signaling cascade in the intestine and 
decreased lifespan. Overexpression of MANF in the fat body, hemocytes, and gut enterocytes 
inhibited age-related inflammation, the loss of epithelial homeostasis and extended the 
lifespan of fruit flies. In contrast, MANF overexpression in neurons reduced the lifespan of 
fruit fly, suggesting distinct function of MANF in different cell types (Sousa-Victor et al., 
2019). Deficiency of MANF in MANF heterozygote mice led to increased infiltration and 
activation of macrophages in white adipose tissue, pancreas, and liver already at 5 months of 
age and signs of cellular senescence at 10 months of age. MANF heterozygote mice displayed 
progressive liver dysfunction associated with activation of JNK signaling, increased 
hepatocyte apoptosis, signs of liver fibrosis and hepatosteatosis (Sousa-Victor et al., 2019). 
Moreover, decreased levels of MANF in the blood was observed in humans with the 
liver disease as well as in the livers of wild type mice after a high-fat diet (HFD). 
Overexpression of human MANF in mice liver fed on HFD led to the reduced accumulation 
of fat and decreased the number of activated macrophages in the liver. Similarly to MANF 
heterozygote mice, specific ablation of MANF in immune cells also resulted in liver damage 
and inflammation, although no fat accumulation was detected. In contrast, specific ablation 
of MANF in hepatocytes did not lead to immune activation, liver damage, or fibrosis, but 
increased fat was observed in the livers of these animals. These results indicated that reduced 
expression of MANF associated with age contributes to disrupted immune and metabolic 
homeostasis. 
In addition, MANF was identified as the factor responsible for rejuvenation (Sousa-
Victor et al., 2019). Animals deficient in MANF did not promote rejuvenation in the old 
partner during heterochronic parabiosis. Hence, these data suggested that MANF is a 
conserved regulator of metabolic and immune homeostasis during aging in animals. 
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1.3.4 MANF therapeutic potential in ischemia models 
Ischemia is a reason of increased incidence rate and death. The discrepancy between the 
blood supply and requirements in oxygen and nutrients within the ischemic organ results in 
the acute tissue hypoxia and microvascular dysfunction caused by a blood clot or 
atherosclerotic plaque (Eltzschig and Eckle, 2011). Reperfusion aiming to restore the blood 
flow and oxygenation is used first for the treatment of ischemia, although this process 
promotes the initiation of immune responses, oxidative stress and cell death programs. Novel 
treatment approaches are aiming to render tissues unaffected to ischemia or restrain 
reperfusion injury and are currently under investigation (Perricone and Vander Heide, 2014; 
George and Steinberg, 2015). 
MANF has also been studied for its protective and restorative effects in rodent models 
of cerebral and myocardial ischemia (Airavaara et al., 2009; Airavaara et al., 2010; 
Glembotski et al., 2012; Yang et al., 2014b). Recombinant and overexpressed MANF 
effectively protected cardiomyocytes from death in simulated ischemia in vitro (Tadimalla et 
al., 2008). MANF protein subjected to the mouse model of myocardial ischemia resulted in 
reduced infarct zone compared to control mice (Glembotski et al., 2012). All three branches 
of the UPR are upregulated in heart damage after myocardial ischemia in rats (Zhang et al., 
2017a), suggesting that the therapeutic potential of MANF in myocardial ischemia depend 
on its role in dampening ER stress. 
Intracortical pretreatment with human MANF and virus vector-mediated MANF 
overexpression just before the cortical stroke model of middle cerebral artery occlusion 
(dMCAO) led to reduced infarct area and promoted neurological and behavioral recovery in 
rats (Airavaara et al., 2009; Airavaara et al., 2010). Similarly, treatment with MANF protein 
2 h after dMCAO led to decreased infarct size and number of apoptotic cells assessed by the 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and cleaved 
caspase-3 staining compared to controls (Yang et al., 2014b). However, it was suggested that 
MANF exerted its beneficial effects by dampening chronic ER stress induced by ischemia 
(Yang et al., 2014b). Other studies revealed that virus vector-delivered MANF in the rat 
model of dMCAO led to functional recovery by the activation of innate immune system at 
the peri-infarct area surrounding cortical stroke (Matlik et al., 2018). Next the authors 
addressed the role of MANF in dMCAO model performed on the NestinCre+/-
::Manfflox(fl)flox/(fl) mice, where MANF was specifically ablated in the neurons of CNS (Matlik 
et al., 2018). The peri-infarct area in the brains of NestinCre+/-:: Manffl/fl mice were larger in 
comparison to the control Manffl/fl, revealing the protective properties of endogenous MANF 
in the mouse neurons. Notable, deficiency of MANF in the NestinCre+/-:: Manffl/fl stroke 
model did not alter the activation of immune cells, indicating differences between the 
functions of endogenous and overexpressed MANF. MANF was also shown to promote 
differentiation and migration of neural progenitor cells to the infarct area in the stroke cortex 
(Tseng et al., 2018). Thus, MANF could mediate faster recovery from stroke by reducing ER 
stress, through activation of the immune response and promoting tissue repair.  
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1.4  Genomic inactivation and overexpression of MANF in non-mammalian species 
1.4.1 MANF knockout in the fruit fly 
Previous studies addressed the biological roles of MANF in vivo in Drosophila melanogaster. 
Expression analysis revealed localization of DmMANF in glia and neurons of CNS and also 
in different peripheral tissues including salivary glands, fat tissue, trachea throughout the 
development of D. melanogaster and in adult ovaries (Palgi et al., 2009; Palgi et al., 2012; 
Stratoulias and Heino, 2015; Lindstrom et al., 2017). During embryo development, 
DmMANF is expressed only a subpopulation of glial cells in the nervous system (Palgi et al., 
2009). However, DmMANF is expressed in both glia cells and neurons in the brain of adult 
D. melanogaster (Stratoulias and Heino, 2015). 
Genomic inactivation of MANF in the fruit fly led to lethality at early larval stages due 
to defects in cuticle formation and the CNS with dramatic changes in dopamine levels and 
dopaminergic axonal degeneration, although the soma of dopamine neurons were intact 
(Palgi et al. 2009). Interestingly, the nervous system of D. melanogaster during 
embryogenesis looked normal due to the maternal contribution of MANF. However, flies, 
that lacked the maternal contribution, died during final stage of embryogenesis, showing a 
more severe CNS phenotype. However, ablation of DmMANF specifically in neurons of 
adult flies did not alter the dopamine system indicating that MANF is required during 
developmental stages and not for the maintenance of dopamine neurons (Stratoulias and 
Heino, 2015). The overexpression of DmMANF in a cell-autonomous manner did not lead 
to the differentiation of dopaminergic neurons (Stratoulias and Heino, 2015). Importantly, 
constrained expression of human MANF (not expressed in muscle, fat body or gastric caeca) 
could rescue the lethal phenotype of the MANF deficient D. melanogaster. The expression 
of C-terminal and N-terminal domains of MANF did not lead to protective effects when 
applied separately or even together, indicating the essential role of intact full-length MANF 
(Lindstrom et al., 2013). It should be noted, however, that the biological activity of MANF 
domains in fly was not analyzed in control experiments. Human CDNF was less potent than 
MANF and required ubiquitous expression to compensate for the loss of DmMANF 
(Lindstrom et al., 2013). Human CDNF was less potent than MANF and required ubiquities 
expression to compensate for the loss of DmMANF (Lindstrom et al., 2013). 
Gene expression analysis of maternal-zygotic DmMANF-deficient embryos identified 
changes in the genes involved in perturbations in membrane transport and major metabolic 
changes (Palgi et al., 2012). The expression levels of genes related to stress, immune 
responses, proteolysis, and cell death were altered in MANF deficient D. melanogaster, as 
well as the genes for dopamine uptake, synthesis and transport were differentially regulated 
(Palgi et al., 2012). More than 40% of gene expression levels known as ER/UPR genes were 
differently regulated in DmMANF mutants. Moreover, increased phosphorylation of eIF2 
was detected in DmMANF larvae indicating the activation of PKR-like ER kinase (PERK) 
pathway (Palgi et al., 2012), although slightly reduced levels of spliced form of X-box 
binding protein 1 (spXbp1) and no changes in GRP78 levels was observed (Lindstrom et al., 
2016). These data indicated the association of MANF deficiency with activation of ER stress 
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and UPR. Specific ablation of DmMANF by RNA interference in glial cells led to acute 
deterioration only in the lamina epithelial glial cells and decreased the lifespan of mutants 
(Walkowicz et al., 2017). Additionally, the sleep and locomotor activity of flies were affected 
by reduced DmMANF in glia or neurons. Overexpression of DmMANF in different 
Drosophila lines led to an increase in genes associated with the damping the oxidative stress, 
suggesting roles for MANF in protecting the dopamine neurons from oxidative stress (Palgi 
et al., 2012).  
Taken together, DmMANF is a vital factor for the development of D. melanogaster. 
Unfortunately, the role of MANF in the peripheral tissues of Drosophila was not addressed. 
1.4.2 MANF knockdown in zebrafish 
Silencing of MANF expression was also studied in zebrafish (Danio rerio) (Chen et al., 
2012). Both MANF and CDNF genes are expressed in zebrafish. To date, CDNF function in 
zebrafish was not addressed. MANF is broadly expressed during embryo development and 
in the tissues of adult zebrafish. Knock-down of MANF protein during the development by 
antisense morpholino oligonucleotides in larval zebrafish did not lead to apparent phenotype 
and changes in viability. However, brain dopamine levels were reduced by half and the 
expression of the two genes for tyrosine hydroxylase, th1 and th2, encoding for the rate-
limiting enzyme for dopamine synthesis,  was reduced as well as number of TH-positive and 
dopamine transporter cells were decreased in specific brain areas. The changes on the 
dopamine level and the th1 / th2 expression could be partly restored by expression of 
exogenous zebrafish Manf mRNA.  
1.4.3 MANF knockdown in Caenorhabditis elegans 
A single ortholog of mammalian MANF/CDNF has been found in C.elegans. Ablation of 
MANF was studied in Caenorhabditis elegans (C.elegans) (Richman et al., 2018). Removal 
of the manf-1 gene in C.elegans resulted in no apparent morphological defects, although 
slower growth was observed in MANF-deficient animals compared to wildtypes. The 
development of the dopaminergic, GABAergic and serotonergic neurons was normal in 
MANF mutants, indicating that MANF is not a key factor for the development and migration 
of neurons in C. elegans.  
However, degeneration of somas of dopamine but not serotonergic or GABAergic 
neurons was observed in MANF mutants with enhanced age progression, implying a vital 
role for manf-1 in neuroprotection of dopaminergic neurons.  
MANF mutants displayed increased levels of inositol-requiring enzyme 1 (IRE1), Xbp1, 
and hsp4, a homolog of the human GRP78, indicating initiation of ER stress and UPR in 
MANF-deficient animals (Bai et al., 2018; Richman et al., 2018). No changes in hsp6 
expression, an ortholog of the vertebrate heat shock proteins (HSP)70 mitochondrial matrix 
specific chaperone, was detected, implying that manf-1 do not regulate mitochondrial UPR 
(Richman et al., 2018). The studies also revealed that human MANF could rescue the age-
related degeneration of dopaminergic neurons C. elegans manf-1 mutants (Bai et al., 2018). 
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Moreover, manf-1 mutants exhibited behavioral defects, particularly slower swimming 
speed. On top of that, MANF-deficient C.elegans displayed that α-Synuclein aggregates were 
significantly enhanced, although it remains to be studied if manf-1 has a direct role in this 
process (Richman et al., 2018). manf-1 was shown to be broadly expressed in several major 
tissues, including intestine, hypoderm, spermatheca, and the nervous system in wild-type 
C.elegans (Bai et al., 2018). However, the expression levels of manf-1 declines with age, 
which did not lead to the degeneration of dopaminergic neurons (Richman et al., 2018). 
Along with the growth delay, neurodegenerative phenotype and enhanced ER stress in manf-
1 mutants, this mutants had fewer offspring, indicating that MANF is required for the proper 
function of the reproductive system of C.elegans.  
1.4.4 MANF knockdown and overexpression in the central nervous system of mice 
In contrast to the neuronal phenotypes of MANF-deficient invertebrates and zebrafish, our 
studies revealed no major effect on the brain phenotype in adult conventional MANF 
knockout mice, where MANF was shown to play role in regulation of the neurite outgrowth 
during cortical development and neuronal migration, implying that MANF is required for 
cortical neurons migration in the developing mouse brain (Tseng et al., 2017). Moreover, the 
activation of UPR was found in neural stem cells (NSCs) isolated from E13.5 MANF-
deficient embryos during differentiation, although no apoptosis was detected. Particularly, 
increased levels of Grp78, spXbp1 and Atf4 mRNA accompanied by the enhanced levels of 
phosphorylated eIF2α were observed at the 8th day of in vitro culture (Tseng et al., 2017), 
indicating the activation of PERK and IRE1cascades. Notably, the Chop mRNA levels were 
not altered in NSCs lacking MANF, suggesting that deficit of MANF in embryonic neurons 
does not alter cell survival mediated by CHOP.  
Recent studies identified the role of MANF overexpression in the CNS neurons, where 
C-terminally tagged human MANF was expressed under the mouse prion promoter (Yang et 
al., 2017). MANF overexpression in the brain of transgenic mice revealed increased feeding 
behavior resulting in increased body weight associated with enhanced adipose tissues in 4-
month-old mice fed with a regular chow diet. The same hyperphagic phenotype was found 
in mice which were induced to overexpress MANF specifically in the hypothalamus using 
MANF expressing adeno-associated virus vectors (AAV). Similarly to MANF-transgenic 
mice, the mice injected with AAV-MANF displayed increased body weights and 
hyperphagia 2 weeks after the injections. However, no alterations were observed in mice that 
received MANF protein into the third ventricle or hypothalamus. These results indicated that 
MANF functions intracellularly. 
Moreover, MANF overexpression in the mouse hypothalamus led to altered insulin 
signaling but did not affect the leptin signaling. Enhanced expression of MANF was 
suggested to recruit phosphatidylinositol-5-phosphate 4-kinase type-2 beta (PIP4k2b) 
localization in the ER, where it becomes active reducing the phosphorylation of AKT, leading 
to impaired insulin signaling cascade and hyperphagia. 
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In accordance, either silencing MANF or neuron-specific deletion of MANF in the 
hypothalamus led to decreased food intake and consequent reduction in body weight due to 
increased AKT phosphorylation and insulin sensitivity (Yang et al., 2017). 
1.4.5 The role of MANF-deficiency in skeletal tissue homeostasis 
MED is a skeletal disease that is characterized by malformation of the cartilage and bones 
leading to moderate dwarfism, joint pain and early development of arthritis and associated 
with gene mutations in matrilin-3, cartilage oligomeric matrix protein and type IX collagen 
(Briggs and Chapman, 2002). The mutation in the gene encoding type X collagen gives rise 
to another type of skeletal disorder called MCDS, which is characterized by dwarfism 
accompanied by short-limbed dwarfism and bowed legs (Wallis et al., 1996). Mutation in 
matrilin-3 and type X collagen genes in mouse represents model of MED and MCDS 
respectively, which are associated with activation of ER stress and UPR in chondrocytes 
(Nundlall et al., 2010; Cameron et al., 2011). Previous studies revealed that Manf gene is 
highly upregulated in the mouse model of multiple epiphyseal dysplasias (MED) and 
metaphyseal chondrodysplasia type Schmid (MCDS) (Nundlall et al., 2010; Hartley et al., 
2013). 
MANF functions in skeletal tissue was addressed by the specific removal of MANF 
from cartilage (Bell et al., 2019). The cartilage-specific ablation of MANF result in a 
chondrodysplasia-like phenotype. The MANF conditional knockout mice had shorter long 
bones (tibia bone ↓5.4%, femur bone ↓3.5%) and reduced skull lengths (↓4.5%). However, 
the cartilage growth plate was morphologically normal. Deficiency of MANF led to 
decreased chondrocyte proliferation and dysregulated apoptosis. Transcriptomic analysis 
revealed increased in ER-resident proteins associated with ER stress and ER stress response 
marker GRP78. Deletion of Manf  specifically from cartilage cells in a mouse model of 
multiple epiphyseal dysplasias (MED) led to the aggravation of the disease demonstrating 
further reduction in bone sizes and bell-shaped rib cages that impeded mice breathing (Bell 
et al., 2019). Hence, MANF is essential for chondrocyte ER homeostasis and bone growth. 
2.  ER stress and UPR 
2.1  Overview of ER stress and UPR 
ER is an important compartment that is required for protein synthesis, folding and transport. 
It is also an important site of Ca2+ storage and production of sterols and lipids (Ron and 
Walter, 2007). Initiation of ER stress and UPR is caused by the accumulation of unfolded 
and misfolded proteins in the ER, resulting in release of GRP78 and activation of intracellular 
signal transduction pathways,  which are regulated by three ER transmembrane proteins - 
PERK, activating transcription factor 6 (ATF6) and inositol-requiring enzyme 1 (IRE1) (Ron 
and Walter, 2007). The initiation of UPR is required in order to restore ER homeostasis (Ron 
and Walter, 2007).  If ER stress remains unresolved the downstream consequences of UPR 
lead toward the inflammation, autophagy and apoptosis (Tabas and Ron, 2011).  
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Figure 2. Schematic illustration of unfolded protein response (UPR) signaling pathways. UPR 
signaling pathways are mediated by PKR-like ER kinase (PERK), activating transcription factor 6 
(ATF6) and inositol-requiring enzyme 1 (IRE1), activation of which aim to restore folding of the 
proteins and increase degradation of the misfolded proteins thereby promoting cell survival. If ER 
stress remains unresolved, UPR cascades are directed to apoptotic signaling. Adapted from (Hetz, 
2012). 
IRE1 pathway is an evolutionarily conserved arm of UPR. In response to unfolded proteins, 
IRE1 dimerization and trans-autophosphorylation trigger its RNase activity, which initiates 
the increased splicing of Xbp1 mRNA into a spXbp1 encoding for an active transcription 
factor. spXbp1 translocates to the nucleus, where it activates the transcriptions of genes for 
ER chaperones, ER-associated degradation (ERAD) machinery, protein quality control and 
phospholipid biosynthesis. IRE1α also triggers the activation of regulated IRE1-dependent 
decay (RIDD) of ER-associated mRNAs, which reduces the ER workload for newly 
synthesized proteins (Pirot et al., 2007; Hollien et al., 2009). Additionally, oligomerized and 
chronically activated IRE1α targets the activation of pro-inflammatory and pro-apoptotic 
proteins. The RNase activity of IRE1α promotes translation of proapoptotic protease caspase-
2 and pro-oxidant thioredoxin-interacting protein (TXNIP), thereby leading to activation of 
NLRP3 inflammasome and caspase-1 that cause maturation and secretion of IL-1β in 
pancreatic beta-cells (Lerner et al., 2012; Upton et al., 2012). Under chronic ER stress 
conditions, IRE1α binds to the scaffold protein tumor necrosis factor receptor-associated 
factor 2 (TRAF2) thereby resulting in activation of apoptosis signal-regulating kinase 
(ASK1) or  caspase-12 at the ER membrane in various cell types (Urano et al., 2000; Yoneda 
et al., 2001; Nishitoh et al., 2002; Son et al., 2014). Finally, activation of IRE1α pathway 
triggers the initiation of pro-inflammatory pathways p38 MAPK and c-Jun N-terminal kinase 
(JNK) pathway via IRE1α/TRAF2/ASK1 complex and NF-κB signaling pathway via 
IRE1α/TRAF2 complex (Urano et al., 2000; Nishitoh et al., 2002; Kaneko et al., 2003; Kim 
et al., 2010). NF-κB stimulates the inducible isoform nitric oxide synthases (iNOS) 
subsequently leading to nitric oxide (NO) formation, that triggers cell death via several 
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mechanisms like oxidative stress, DNA damage via necrosis pathway through poly (ADP-
ribose) polymerase (PARP) and via apoptosis pathway mediated through p53 signaling, or 
dysregulation of cytosolic calcium (Murphy, 1999).  
The activation of PERK pathway leads to activation of the initiation factor eukaryotic 
translation initiator factor (eIF2α), phosphorylation of which is controlled by four unique 
kinases general control non-derepressible-2 kinase (GCN2), double-stranded RNA-activated 
protein kinase (PKR), PKR-like endoplasmic reticulum kinase (PERK), and heme-regulated 
inhibitor kinase (HRI) depending on stress response stimuli (Donnelly et al., 2013). 
Phosphorylation eIF2α leads to suppressed initiation of protein synthesis to relieve the ER 
load and increased translation of transcription factor ATF4  (Harding et al., 1999; Harding et 
al., 2000), which initiates the expression of ATF3 and CHOP and controls genes involved in 
apoptosis and autophagy (Harding et al., 2003; Schroder and Kaufman, 2006). CHOP 
activates the growth arrest and DNA damage protein (GADD34), leading to 
dephosphorylation of eIF2α via protein phosphatase 1 (PP1) and protein translation recovery 
in cells recovering from ER stress. During ER stress ATF3 potentiates the GADD34 
expression, which contributes to feedback de-phosphorylation of eIF2α (Jiang et al., 2004). 
Transcriptional induction through ATF4 and CHOP enhances the pro-apoptotic protein 
production, depletion of ATP and formation of reactive oxygen species (ROS) resulting in 
oxidative stress and cell death (Han et al., 2013). Moreover, CHOP initiates cell death by 
constraining the anti-apoptotic regulators BCL-2 family and stimulating the expression of 
pseudokinase tribbles homolog 3 (TRIB3), an inhibitor of AKT (McCullough et al., 2001; 
Du et al., 2003; Marciniak et al., 2004). The trib3 expression is also regulated by ATF4 
(Cunard, 2013). Additionally, up-regulation of the transcription factors ATF4, CHOP and 
TRIB3 leads to autophagy induction (Salazar et al., 2009). Hence, CHOP expression 
increases ER protein workload and consequently fosters ER stress and apoptotic cell death 
(Brush et al., 2003; Feldman et al., 2005). Additionally, phosphorylated eIF2α initiates the 
NF-κB cascade due to repression of its inhibitor (IκBα) translation (Deng et al., 2004). 
Finally, the initiation of PERK pathway leads to nuclear translocation of nuclear factor 
erythroid 2–related factor 2 (NRF2) that possesses the cytoprotective properties during ER 
stress (Cullinan et al., 2003; Ma, 2013; Mukaigasa et al., 2018).  
Upon activation of ER stress, ATF6 is translocated to the  Golgi, where it is cleaved by 
site 1 and 2 proteases, resulting in the release of its cytosolic domain fragment (ATF6f). 
ATF6f is a transcription factor that controls the expression of genes encoding the GRP78 and 
GRP94, spXbp1, CHOP, ERAD components, and genes implicated in regulation of lipid 
synthesis (Kaufman et al., 2010). ATF6α isoform carries functions of ER stress-induced gene 
expression subjected to rapid degradation, while ATF6β may negatively regulate ATF6α, 
acting as a feedback loop to regulate ATF6-dependent signaling (Thuerauf et al., 2007).  
2.2  Dysregulated UPR in pathological states in human and animal models 
The emerging evidence reveals that ER stress and UPR contributes to the pathophysiological 
and metabolic changes of many diseases in human and mouse models including diabetes, 
obesity, liver diseases, and neurodegenerative diseases (Kaufman, 2002; Hetz et al., 2019). 
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The association of ER stress and UPR with the disease pathology of diabetes and other 
metabolic disorders has been well documented and will be reviewed in detail in chapter 3.5. 
The function of UPR in the physiology of the nervous system is not well understood, although 
several indications have been proposed. Studies of Hayashi et al. revealed that Xbp1 is 
essential for BDNF-induced outgrowth via regulation of GABAergic markers (Hayashi et al., 
2007; Hayashi et al., 2008). Genetic variants in the Xbp1 gene were associated with bipolar 
disorder and schizophrenia (Kakiuchi et al., 2003). Mutation in the PERK gene EIF2AK3 
was found in a child with early signs of neurodegeneration (Bruch et al., 2015), indicating 
essential role for PERK in the neurons. Moreover, phosphorylated PERK and eIF2 was 
detected in the post mortem brain samples from patients with several neurodegenerative 
diseases including Alzheimer's disease, Parkinson's disease and sporadic amyotrophic lateral 
sclerosis (Hoozemans et al., 2007; Atkin et al., 2008; Hoozemans et al., 2009; Stutzbach et 
al., 2013). Interestingly, specific ablation of PERK in the neurons of 8 weeks old mice did 
not affect the viability of the neurons or axons under physiological conditions (Stone et al., 
2019). However, PERK neuronal inactivation in the mouse model experimental autoimmune 
encephalomyelitis (EAE) exacerbated axon degeneration, neuron loss and demyelination 
(Stone et al., 2019). Neuron-specific ATF4 ablation did not aggravate the EAE. Studies on 
GCN2 knockout mice demonstrated that translational control of ATF4 is required for 
hippocampal synaptic plasticity, learning and memory (Costa-Mattioli et al., 2005). Reduced 
ATF4 expression in the mouse brain led to increased long-term synaptic plasticity and 
memory formation (Chen et al., 2003). 
Neurodegenerative diseases differ in their clinical and pathological states but share a 
common sign – accumulation of misfolded disease‐specific proteins associated with neuronal 
apoptosis. Alzheimer's disease is characterized by the aggregation of amyloid‐beta and 
hyperphosphorylated tau, while the accumulation of α‐synuclein was found the brains of 
human individuals with Parkinson's disease.  The disease‐specific TDP‐43, FUS or SOD1  
proteins are found in amyotrophic lateral sclerosis. However, it remains unclear if the 
accumulation of these disease‐specific aglomerates triggers the activation of UPR or ER 
stress precedes these pathological state.  
2.3  Regulation of MANF and CDNF expression by ER stress 
Microarray studies revealed that MANF gene is upregulated in response to ER stress-induced 
by neurotoxins (Holtz and O'Malley, 2003). Other UPR inducers including tunicamycin (N-
glycosylation inhibitor), thapsigargin (sarco/ER Ca2+ transporting ATPase inhibitor), 
lactacystin (proteasome inhibitor) and 1,4-Dithiothreitol (DTT, reducing agent) are also 
known to up-regulate MANF expression in cell lines and primary cells (Apostolou et al., 
2008; Hellman et al., 2011; Glembotski et al., 2012; Henderson et al., 2013). Expression of 
MANF mRNA and protein is also enhanced under multiple pathophysiological conditions 
which are related to ER stress. In vivo, increased MANF expression along with initiation of 
ER stress was found in pancreatic beta-cells of diabetic Akita mice (Mizobuchi et al., 2007) 
and chondrocytes in genetic mouse models of chondrodysplasias (Hartley et al., 2013). 
Additionally, MANF expression was up-regulated in hypoxia-related conditions such as 
myocytes in a mouse model of heart ischemia (Tadimalla et al., 2008; Glembotski et al., 
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2012) and in transient global and focal cerebral ischemia (Lindholm et al., 2008; Yu et al., 
2010). Increased MANF expression was also detected in the developing mouse brain upon 
treatment with tunicamycin (Wang et al., 2015). Moreover, enhanced expression of MANF 
was observed in kidney cells after activation of ER stress (Kim et al., 2016; Kim et al., 2017). 
Moreover, MANF expression is dependent on XBP1- and ATF6-induced expression 
(Tadimalla et al., 2008; Wang et al., 2018), implying that MANF is ER stress-related protein. 
The mechanism whereby MANF expression is increased might depend on the ER stress 
responsive elements (ERSE) detected in the MANF promoter that are recognized by spXBP1 
and ATF6, thus upregulated in the UPR (Lee et al., 2003; Mizobuchi et al., 2007; Tadimalla 
et al., 2008; Yang et al., 2014a; Wang et al., 2018). Moreover, MANF expression is 
dependent on XBP1- and ATF6-induced expression (Tadimalla et al., 2008; Wang et al., 
2018), implying that MANF is ER stress-related protein. 
The first indication that MANF is a secreted factor was provided in the work of Petrova 
et al. when MANF was discovered (Petrova et al., 2003). Further studies identified that unlike 
other ER stress-induced proteins, MANF could be secreted in stress-regulated conditions. 
Secretion of MANF was induced by thapsigargin (Glembotski et al., 2012; Henderson et al., 
2013) and ischemia-reperfusion injury (Glembotski et al., 2012), but not tunicamycin, 
although the previous work of Tadimalla et al. showed MANF secretion from primary rat 
cardiac myocytes upon tunicamycin treatment (Tadimalla et al., 2008). Both thapsigargin and 
myocardial ischemia followed by reperfusion dysregulate calcium in the ER leading to 
initiation of ER stress and UPR, and MANF secretion that can be regulated via two possible 
mechanisms: interaction with GRP78 (Glembotski et al., 2012) and C-terminal RTDL ER 
retention motif of MANF that interacts with KDEL-receptors and promotes MANF secretion 
(chapter 1.1). Further studies revealed that MANF is also secreted to the urine after acute 
kidney injury after intraperitoneal tunicamycin injection or tubular ischemia/reperfusion 
(Kim et al., 2016). Moreover, MANF is also secreted in mouse models of chondrodysplasias 
(Hartley et al., 2013) and congenital nephrotic syndrome (Kim et al., 2016).  
In contrast to MANF, there is less published data related CDNF responses to ER stress 
and UPR. CDNF expression has been shown to be up-regulated in response to tunicamycin-
induced ER stress in primary rat hippocampal neurons and cultured rat myoblast cells (H9c2) 
in vitro (Liu et al., 2018; Zhang et al., 2018), although no effect was seen in studies with 
human bone osteosarcoma epithelial cell line (U2OS) (Apostolou et al., 2008). CDNF 
upregulation in vivo and increased secretion upon ER stress conditions has not been 
documented yet. 
3.  Diabetes mellitus 
Diabetes mellitus (DM) is a heterogeneous group of metabolic disorders characterized by 
elevated blood glucose levels (hyperglycemia), caused by either insulin deficiency and/or 
insulin resistance. Common symptoms of DM are thirst, fatigue, polyuria, and changes in 
weight. Long-term complications of untreated diabetes include peripheral neuropathy, 
nephropathy, retinopathy, foot injuries, bone and joint problems, teeth and gum infections, 
cardiovascular disease and stroke, leading to massive morbidity and mortality. Based on the 
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estimations from the International Diabetes Foundation of 2017, DM affected 425 million 
people worldwide and is rapidly increasing with an estimation of 629 million people 
worldwide in 2045 (https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html).   
DM is classified into different forms: type 1 diabetes (T1D), type 2 diabetes (T2D) and 
monogenic diabetes. An estimated 10% of diabetes cases in the world are T1D, while the 
majority being T2D. Other types of diabetes account for roughly 1-5%.  
3.1  Type 1 Diabetes 
T1D is characterized by hyperglycemia due to the reduction of insulin secretion that is caused 
by the autoimmune attack of pancreatic beta-cells. The disease manifestation occurs when a 
significant number of the functional beta-cell mass is lost (40-80% depending on the strength 
of the adverse immune response, the age of disease onset, periods of remission (Weir and 
Bonner-Weir, 2013; Chen et al., 2017)) and individual’s blood glucose begins to deviate 
(Figure 2). T1D is thought to be promoted by the combination of genetic, epigenetic and 
environmental factors.  Several environmental risk factors were suggested to trigger the beta 
cell autoimmunity including viral infections (enteroviruses), intestinal microbiota, 
vaccinations, excess of hygiene, dietary factors, toxins and chemical compound in foods or 
water (Rewers and Ludvigsson, 2016). 
 
Figure 2. Suggested staging of type 1 diabetes (T1D). The pathogenesis of T1D is characterized by 
three stages, including stage 1, when no symptoms occur but beta-cell autoantibodies can be detected; 
stage 2, asymptomatic state, however functional beta-cell mass is gradually decreasing and 
biochemical tests may detect impaired glucose tolerance; stage 3, clinical onset of type 1 diabetes 
with its classic symptoms of polyuria, polydipsia and polyphagia, persistent hyperglycemia, 
remaining beta-cell generate and secrete insufficient insulin, beta-cell autoantibodies are still 
established, although some of them may have been lost. *beta‑cell directed autoimmunity initiated by 
the beta-cell autoantibodies occuring months to years before the onset of the beta-cell loss. Adapted 
from (Katsarou et al., 2017). 
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T1D is defined as juvenile diabetes due to the age at the onset of the disease or insulin-
dependent diabetes because insulin therapy is required for survival of the diagnosed 
individual. The evidence implies that beta-cell dysfunction and destruction begins after the 
onset of autoimmunity initiated by the beta-cell autoantibodies against different beta-cell 
proteins, which includes glutamate acid decarboxylase (GADA65a), insulin,  zinc transporter 
8 and insulinoma-associated antigen-2 (Couper et al., 2014). Roughly 70% of diabetic 
patients represent three or four autoantibodies, while only 10% have a single autoantibody. 
The duration from the appearance of autoantibodies until the clinical onset of diabetes might 
vary from a few months to decades. 
 
Figure 3. Type 1 diabetes mellitus (T1D) is an autoimmune disease. Antigen detection by B cells and 
dendritic cells (DCs) in the pancreatic islets triggers the activation of autoantigen-specific helper 
CD4+ T cells and cytotoxic CD8+ T cells. The activated T cells trigger the generation of pro-
inflammatory cytokines, which contribute to the destruction of beta cells. The appearance of the beta-
cell autoantigens results in generation of autoantibodies that target pancreatic islets and can be used 
as biomarkers of asymptomatic diabetes. Possible interactions between B cells and CD8+ T cells or 
DCs are marked with dashed arrows. BCR, B cell receptor; TCR, T cell receptor. Adapted from 
(Katsarou et al., 2017). 
It is commonly accepted that beta cell destruction is triggered by the innate immune system, 
inflammation and activated autoreactive lymphocytes. The pathogenic pathway of the beta-
cell destruction is not fully understood in humans, although some of the mechanisms were 
explained in mouse models such as non-obese diabetic mouse (NOD) and RIP–LCMV (rat 
insulin promoter-lymphocytic choriomeningitis) mouse models (Mathis et al., 2001; Lehuen 
et al., 2010). Cytotoxic T cells CD8+, helper T cells CD4+, natural killer cells, and 
macrophages promote damage of the beta-cells (Figure 3) (Lehuen et al., 2010). The 
activation of the innate immune system stimulates the release of proinflammatory cytokines 
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(Cabrera et al., 2016). The emerging evidence suggests that ER stress is involved in the 
pathogenesis of T1D  and it will be reviewed in chapter 3.5 of this thesis.  
Latent autoimmune diabetes in adults (LADA) is a rare form of autoimmune slowly 
progressing insulin-dependent diabetes that occurs in adults usually older than 30 years of 
age (Leslie et al., 2006). LADA was first defined in the early 1990s to characterize a group 
of patients who share the clinical and metabolic symptoms with both T1D and T2D (Tuomi 
et al., 1993). LADA is also referred to as 1.5 TD and diagnosed with three parameters based 
on Immunology of Diabetes Society: manifestation at the adult age (>30 years), the presence 
of diabetes-associated islet-targeting autoantibodies, and no need in insulin therapy at the 
onset of disease for at least 6 month (Juneja and Palmer, 1999; Fourlanos et al., 2005).  
3.2  Type 2 Diabetes 
T2D is a significant public health problem around the world. T2D is far more common 
compared to the other types of diabetes and is characterized by hyperglycemia that is caused 
by impaired insulin secretion and insulin resistance (DeFronzo et al., 2015). The etiology of 
T2D is highly associated with lifestyle factors accompanied by the genetic and environmental 
aspects. Obesity-related insulin resistance rises the incidence of T2D. The pathophysiology 
and progression of the T2D are variable among individuals. Some of the newly diagnosed 
patients are asymptomatic, whereas others have already severe hyperglycemia or even 
diabetic ketoacidosis (American Diabetes, 2009). Treatment of T2D includes changes in 
lifestyle (healthy diet, maintaining a body mass index of ≤25, physical exercising, avoiding 
smoking and consuming alcohol in moderation), and antidiabetic and anti‑obesity 
medications (Hu et al., 2001; Schellenberg et al., 2013; Garvey et al., 2014). Upon treatment, 
severe hyperglycemia in T2D individuals can be reverted as a result of at least partial 
recovery of beta-cell function and decreased insulin resistance. 
The beta-cell dysfunction in the presence of impaired insulin sensitivity is central to the 
pathology of T2D. Beta-cell increase insulin secretion to compensate for normoglycemia in 
obesity, and insulin-resistant states lead to enhanced beta cell function and expansion of the 
beta-cell mass (Prentki and Nolan, 2006). Several factors are known to trigger these 
compensatory effects such as increased nutrition (especially increased levels of glucose and 
free fatty acids (FFAs), growth factor signaling (insulin, placental lactogen, prolactin, etc.), 
and enhanced levels of and sensitivity to incretin hormones (glucagon-like peptide 1 (GLP-
1)) (Prentki and Nolan, 2006; Auffret et al., 2013). It is still debated whether the islet 
expansion is caused by the proliferation of existing beta-cell and/or neogenesis of new beta-
cells from pancreatic ductal cells  (Bonner-Weir et al., 2010). If beta-cells fail to compensate 
for the enhanced demand, it will lead to beta-cell exhaustion, leading to reduced insulin 
secretion (Del Guerra et al., 2005). Several molecular mechanisms are involved in beta-cell 
de-differentiation and death in T2D including gluco- and lipotoxicity, mitochondrial 
dysfunction, oxidative stress, ER stress and inflammation (Alejandro et al., 2015). The 
implication of ER stress in the pathology of T2D will be discussed in the separate chapter 
3.5.2.  
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Gestational diabetes mellitus (GDM)  occurs during pregnancy in women and affects 
both the mother and unborn child throughout the pregnancy. Relatively high levels of human 
placental lactogen, leptin, prolactin, and cortisol from the placenta during the pregnancy may 
lead to the development of insulin resistance (Jao et al., 2013). GDM appears when beta-cells 
are not able to secrete enough insulin in the face of increasing insulin resistance (Cundy et 
al., 2014; McCabe and Perng, 2017). Women affected by GDM are at higher risk of 
developing metabolic syndrome and T2D over the years after their pregnancy, and their 
children have greater risk of developing obesity and T2D early in life (Group, 2002). 
3.4  Monogenic diabetes 
Monogenic diabetes or insulin-dependent form of DM is a rare type of DM that occurs due 
to beta-cell dysfunction and is caused by a single gene mutation essential for beta-cell 
development and regulation. It shares characteristics of both T1D or T2D and is therefore 
frequently misdiagnosed. There are two main classifications of monogenic diabetes: neonatal 
diabetes (NDM) and maturity-onset diabetes of the young (MODY). NDM manifests in the 
first 6 months of life and occurs rarely. Typically, newborns display intrauterine growth 
retardation and diabetes in the first week after the birth. If NDM develops a permanent 
condition, it is defined as permanent NDM (PNDM), while if it is presented transiently with 
apparent remission, it is called transient NDM (TNDM) (Murphy et al., 2008).  
The most common mutations leading to PNDM are mutations in KATP channel genes 
and the proinsulin gene (INS). In more detail,  mutations have been detected in KATP channel 
encoding genes KCNJ11 (encodes the inwardly rectifying potassium channel Kir6.2) and 
ABCC8 (encodes the sulfonylurea receptor [SUR] 1), leading to impaired insulin secretion 
and hyperglycemia (Gloyn et al., 2004; Flanagan et al., 2009).  
To date, about 50 different mutations in the INS gene have been documented. These 
mutations impair the biosynthesis of insulin at a variety of different steps. Many of these 
mutations result in the misfolding of proinsulin with early manifestation of autosomal 
dominant diabetes, although some trigger diverse cellular and molecular mechanisms causing 
beta cell failure and diabetes. ER stress and UPR are triggered due to accumulation of 
misfolded proinsulin in the ER (Liu et al., 2005). The mutations in the INS gene are inherited 
in an autosomal dominant manner leading to PNDM, also known as Mutant INS-gene 
Diabetes of Youth (MIDY) (Liu et al., 2010).  
Other rare cases of PNDM are not discussed in this thesis. Other gene mutations related 
to the activation of ER stress and UPR will be discussed in chapter 3.5.3.  
MODY is diagnosed in young adults before the age of 25 years. The leading cases of 
MODY are caused by the mutations in the glucokinase (GCK) (MODY 2) and hepatocyte 
nuclear factor (HNF)1A/4A (MODY 3 and MODY 1) genes (Kim, 2015). GCK mutations 
cause an asymptomatic form of the disease with the mild and stable fasting hyperglycemia 
usually requiring no particular treatment. In contrary, HNF1A and HNF4A mutations result 
in progressive beta-cell dysfunction and elevated blood glucose levels that may lead to 
microvascular complications.  
21 
Hence, it is essential to precisely identify the genetic etiology of diabetes in order to 
select an appropriate treatment. 
3.5  Chronic activation of unfolded protein response (UPR) as a cause of the beta-cell 
death  
The beta-cells are continuously exposed to low levels of UPR activation as IRE1α and ATF6 
signaling pathways are vital in normal ER biogenesis, required for differentiation of secretory 
cells (Calfon et al., 2002; Sriburi et al., 2007; Scheuner and Kaufman, 2008; Bommiasamy 
et al., 2009; Xin et al., 2018). However, high-stress conditions lead to beta-cell 
dedifferentiation, one of the mechanisms contributing for their dysfunction in diabetes 
(Akirav et al., 2008; Szabat et al., 2012; Weir et al., 2013; Brereton et al., 2014).  
3.5.1 UPR in the pathogenesis of T1D 
Chronic activation of the UPR and islet inflammation in T1D are highly connected (Brozzi 
and Eizirik, 2016). The mechanisms underlining the cytokine-induced beta-cell death are ER 
stress, ER calcium depletion, elevation of cytosolic calcium levels, and oxidative stress 
caused by ROS accumulation (Cardozo et al., 2005; Miani et al., 2012; Hara et al., 2014). 
Additionally, pro-inflammatory cytokines activate the JNK and NF-B signaling cascades, 
leading to iNOS expression and NO formation followed by beta-cell death (Eizirik et al., 
2009; Gurzov and Eizirik, 2011; Hasnain et al., 2016). However, the pathways behind 
cytokine-induced ER stress in beta-cells differ in humans and rodents. The exposure of beta-
cells to cytokines results in SERCA2b inhibition (pump driving Ca2+ from cytosol into the 
ER), depleting ER Ca2+ (Cardozo et al., 2005). Activation of ER stress and UPR by pro-
inflammatory cytokines in human and mouse beta-cells is independent of NO formation 
(Allagnat et al., 2012; Brozzi et al., 2015). By contrast, cytokine-induced NF-B activation 
lead to NO production and initiation of the ER stress in beta-cells (Cardozo et al., 2005).  
Several studies showed that cytokine-induced activation of PERK and IRE1α/Xbp1 signaling 
pathways in beta-cells (Cardozo et al., 2005; Brozzi et al., 2015). Moreover, UPR by itself 
triggers the activation of inflammatory genes besides responding to inflammation. Chronic 
ER stress initiates the activation of several inflammatory pathways mediated by oligomerized 
IRE1α - JNK, p38 MAPK and NF-κB, which trigger beta-cell degeneration in diabetes 
(Brozzi and Eizirik, 2016). 
The beta-cell dysfunction and death in diabetes are associated with the mitochondrial 
apoptotic pathway. Pro-apoptotic members of the Bcl-2 family, elevated levels of 
intracellular calcium, and ROS trigger cytochrome c release from mitochondria leading to 
beta-cell death (Gurzov and Eizirik, 2011).  Pro- and anti-apoptotic proteins of Bcl2 family 
affect mitochondrial apoptotic pathway by regulating the permeabilization of the 
mitochondrial membrane by pore formation (Adams and Cory, 1998; Danial and Korsmeyer, 
2004; Suhaili et al., 2017). Anti-apoptotic members such as Bcl-2, Bcl-XL and MCL-1 
regulate cell survival by constraining the Bcl-2 pro-apoptotic proteins. The activation of pro-
apoptotic members (Bad, Bim, Bid, Bcl10, Noxa, and Puma) affect the activity of anti-
apoptotic molecules, consequently leading to the release of the pro-apoptotic effectors Bax 
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and Bak initiating the induction of mitochondrial permeability followed by release of 
cytochrome c and production of ROS (Danial and Korsmeyer, 2004; Strasser, 2005). 
Additionally, mitochondrial ROS production is enhanced upon increased cytosolic Ca2+ 
(Brookes et al., 2004), leading to ER Ca2+ release and beta-cell apoptosis mediated by 
cytochrome c via protease calpain-2 and caspases (Ramadan et al., 2011; Hara et al., 2014; 
Tsuchiya et al., 2016). Pro-inflammatory cytokines inhibit expression of pro-survival Bcl-2 
proteins in pancreatic islets (Piro et al., 2001; Trincavelli et al., 2002; Van de Casteele et al., 
2002) and Bcl-2 overexpression in beta-cells protects from cytokine-induced apoptosis in 
vitro (Rabinovitch et al., 1999; Barbu et al., 2002; Tran et al., 2003). Moreover, Bak/Bax was 
shown to increase RNase/kinase activity of IRE1α, followed by activation of XBP1 target 
genes and JNK pathway leading apoptosis (Hetz et al., 2006). 
In T1D, it has been suggested that inflammation may lead to ER stress in beta-cells that 
in turn enhances beta-cell-inflammatory responses in several mouse models and human 
patients (Eizirik et al., 2008; Cnop et al., 2012). Inflamed islets from individuals with T1D 
display increased levels of ATF3, BiP/GRP78 and CHOP, although the expression levels of 
spXBP1 were not affected (Hartman et al., 2004; Marhfour et al., 2012).  Importantly, CHOP 
knockdown led to decreased cytokine-induced beta-cell death and reduced activity of NF-κB 
signaling in primary human beta-cells and rat insulinoma-derived clonal (INS1-1E) cell line 
(Allagnat et al., 2012).  
Based on the symptomatic and pathophysiological characteristics of T1D in humans, 
non-obese diabetic (NOD) mouse, which develops spontaneous auto-immune diabetes 
characterized by islet infiltration of inflammatory cells (insulitis), represent a mouse model 
of T1D (Anderson and Bluestone, 2005). Insulitis manifestation occurs in NOD mice by the 
age of 3 weeks and the onset of diabetes appears between the age of 12-20 weeks indicative 
for the decrease in beta-cell mass and overt hyperglycemia (Fujino-Kurihara et al., 1985). 
Several studies described the increased ER stress in the beta-cells of NOD mice contribute 
to the pathogenesis of diabetes. Tersey et al. identified increased ER stress and upregulation 
of UPR genes in the beta-cells before the development of diabetes in NOD mice (Tersey et 
al., 2012). Moreover, NF-κB signaling was also activated in the beta-cell of pre-diabetic 
NOD mice.  Increased levels of Grp78, spXbp1 and Chop mRNA were observed in the pre-
diabetic NOD islets at the age of 6 weeks, while Atf4 mRNA levels were decreased. 
Additionally, Serca2b mRNA was downregulated in 10 weeks old NOD islets, suggesting 
altered ER Ca2+ homeostasis. Similarly, in studies of Morita et al., islets of pre-diabetic mice 
showed increased mRNA levels of Grp78 at 8 weeks of age, spXbp1 at 8 and 10 weeks of 
age, and increased levels of auto-phosphorylated IRE1α at 10 and 12 weeks of age (Morita 
et al., 2017). Additionally, high levels of Txnip mRNA was detected in islets isolated from 
12 weeks old NOD mice. Importantly, restraining the IRE1α activity by anti-oncogenic 
medication imatinib nearly fully reversed diabetes in NOD mice (Morita et al., 2017). The 
protective effects of imatinib were achieved by mitigating the interaction between the IRE1α 
and ABL tyrosine kinases found for its pro-apoptotic effects for beta-cells (Morita et al., 
2017).  
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3.5.2 UPR in the pathogenesis of T2D 
T2D is characterized by hyperglycemia due to insulin resistance in adipose tissue, muscles 
and liver, and/or decreased beta-cell insulin secretion, dysfunction, chronic ER stress and 
death due to chronic hyperglycemia and hyperlipidemia (Kahn et al., 2006; Cnop et al., 2010; 
Cnop et al., 2012).  
Increased circulating free fatty acids (FFAs) due to over-nutrition and obesity results in 
beta-cell dysfunction and death in T2D (Prentki and Nolan, 2006). Both enhanced levels of 
saturated and unsaturated FFAs provoke UPR response in beta-cells by activating different 
signaling pathways (Cnop et al., 2010). Production of proinsulin and glucose-stimulated 
insulin secretion in beta-cells are inhibited by both unsaturated and saturated FFAs 
(Bollheimer et al., 1998).  Saturated FFA, such as palmitate, led to activation of PERK 
(increased levels of ATF4, ATF3 and CHOP), IRE1α/Xbp1 (increased levels of spXbp1) and 
ATF6 pathways leading to beta-cell apoptosis (McGarry and Dobbins, 1999; Kharroubi et 
al., 2004; Cunha et al., 2008; Cnop et al., 2010). However, unsaturated FFAs, such as oleate, 
did not cause the activation of PERK and IRE1α signaling cascades, although it led to 
initiation of ATF6 pathways similarly to saturated FFAs (Cunha et al., 2008; Thorn and 
Bergsten, 2010). Additionally, saturated FFAs can initiate the UPR by perturbation of ER 
Ca2+ stores via diminishing the activity of SERCA (Back and Kaufman, 2012). Chronic 
hyperglycemia enhances the production of proinsulin and formation of islet amyloid 
polypeptide (IAPP) in the beta-cells (Haataja et al., 2008), following by increase in misfolded 
IAPP and ROS production. ROS and toxic IAPP disrupts ER Ca2+ homeostasis activates the 
UPR pathways leading to pro-apoptotic signals and proinsulin mRNA degradation (Hasnain 
et al., 2016). Moreover, IRE1α/Xbp1 pathway is activated in rodent beta-cells by acute and 
chronic glucose exposure in vitro (Lipson et al., 2006; Elouil et al., 2007).  
Obesity is characterized by chronic inflammation with enhanced levels of pro-
inflammatory cytokines and decreased levels of anti-inflammatory adipokines that originate 
from white adipose tissues (Pereira and Alvarez-Leite, 2014). In agreement with these 
observations, the enhanced levels of circulating pro-inflammatory cytokines were observed 
in early stages of T2D and increased gradually with the disease progression (Duncan et al., 
2003; Grossmann et al., 2015). Similarly to the pathogenesis of cytokine-induced T1D, the 
circulating pro-inflammatory cytokines may induce ER stress and UPR in T2D islets. The 
increased levels of UPR markers such as Bip, Chop and TXNIP and decreased expression of 
IkBα and NRF2 were detected in the peripheral mononuclear cells in T2D patients 
(Cominacini et al., 2015; Lenin et al., 2015). However, it remains unclear whether beta-cell 
survival is affected by relatively low amounts of circulating cytokines. FFAs is another cause 
of pro-inflammatory responses through NF-κB signaling in the beta-cells (Eguchi et al., 
2012; Pal et al., 2012).   In vitro studies revealed that palmitate induces ER stress in human 
islets along with mild activation of NF-κB cascade and pro-inflammatory response, similar 
to T2D islets (Cunha et al., 2008).  Hence, FFAs-induced inflammation promotes beta-cell-
ER stress and disease progression. 
In T2D, increased levels of UPR proteins Grp78, p58, activation of ATF3 and CHOP 
accompanied with distended ER was demonstrated in pancreatic islets (Hartman et al., 2004; 
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Marchetti et al., 2004; Laybutt et al., 2007). On the contrary, Engin et al. identified that islets 
of T2D patients display reduced levels of spXBP1, ATF6 and barely any phospho-eIF2α, 
suggesting that deficient beta-cell UPR leads to beta-cell death (Engin et al., 2014). The 
development of diabetes in leptin receptor-deficient db/db mice strongly resembles human 
T2D (Hummel et al., 1966; Coleman and Hummel, 1967; Coleman, 1978). The db/db 
(C57BL/KsJ) mouse develops hyperinsulinemia within 2 weeks of age and obesity by 3 to 4 
weeks leading to hyperglycemia at age 8 weeks and beta-cell dysfunction (Dalboge et al., 
2013). Enhanced beta-cell mass appear 10 weeks old animals with the decline in older 
animals at 34 weeks of age.  
Importantly, impaired UPR signaling was observed in the insulin-resistant db/db mouse 
islets including enhanced expression of phosphor-eIF2α, increased splicing of Xbp1 mRNA 
and expression of CHOP (Yusta et al., 2006; Laybutt et al., 2007). Similarly, significant 
upregulation in BiP, Grp94 and p58 mRNA levels and increase in pro-apoptotic Atf3, Chop, 
and Trib3 were detected in the islets of prediabetic db/db mice at 6 weeks of age (Chan et al., 
2013), revealing that ER stress is implemented in the development of T2D in db/db mice. 
Similarly to leptin receptor-deficient mice, leptin-deficient ob/ob mice is a model of obesity, 
insulin resistance and hyperinsulinemia at 3–4 weeks of age, with obesity evident by 4 weeks 
of age accompanied by hyperlipidemia (Lindstrom, 2007; Srinivasan and Ramarao, 2007). 
However, the ob/ob mouse model lacks complete beta-cell failure, indicating that diabetes is 
not acute (Coleman, 1978). Interestingly, enhanced expression of Bip, Grp94, p58 and 
spXbp1 mRNA was detected in the ob/ob islets, while the expression of pro-apoptotic Atf3, 
Chop, and Trib3 was not changed (Chan et al., 2013). Thus the mild UPR could explain the 
lack of beta-cell failure in these mice. 
Moreover, pathogenesis of T2D is associated with ER stress not only in pancreatic beta-
cells but also in various metabolic tissues, such as hypothalamus, liver, adipose tissues and 
muscle, leading to the progression of T2D (Cnop et al., 2012). Chronic ER-stressed induced 
inflammation in metabolic tissues of obese individuals results in suppressed insulin receptor 
signaling (Gregor and Hotamisligil, 2011; Garg et al., 2012). UPR response in hypothalamus 
leads to activation of inflammatory responses, which cause leptin/insulin resistance during 
the obesity onset (Cnop et al., 2012). ER stress in the liver resulted in the development of 
steatosis and insulin resistance, and lipid metabolism in the liver is regulated by UPR. UPR 
response in adipose tissues causes inflammation and regulates adipokine secretion. 
Particularly, PERK and IRE1α pathways were found to be activated in the liver and adipose 
tissues of obese animals (Ozcan et al., 2004). Initiation of JNK pathway through IRE1α and 
TRAF2 was shown to cause insulin resistance in T2D (Aguirre et al., 2000; Hirosumi et al., 
2002). Additionally, it was shown that saturated FFAs initiates the activation of UPR in the 
muscle (Cnop et al., 2012). 
3.5.3 UPR in the pathogenesis of monogenic diabetes 
The MIDY syndrome is a direct evidence of diabetes caused by the accumulation of 
misfolded proteins and ER stress, involving misfolding mutations in INS gene (Liu et al., 
2015b). In accordance with MIDY syndrome, ER stress-associated beta-cell death was found 
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in the islets of Akita mouse model (heterozygous mice carry a mutated Ins2 gene), which 
develop diabetes in early life (Yoshioka et al., 1997; Oyadomari et al., 2002b). The mutation 
in Ins2 gene in Akita mouse leads to disturbed oxidative folding and trafficking of pro-insulin 
to the Golgi and secretory granules. Additionally, pancreatic beta-cell of Akita mouse 
demonstrated dilated ER, a hallmark for ER dysfunction, and a reduced number and size of 
secretory granules (Wang et al., 1999). As a consequence of these processes, Grp78 and Chop 
mRNA were upregulated in the pancreases of Akita mouse leading to the beta-cell apoptosis 
(Oyadomari et al., 2002b). However, recent studies performed on Akita mouse model as well 
as newly developed induced pluripotent stem cells (iPSCs) from humans with insulin 
mutation C96R (the mutation in the same cysteine as in Akita mouse C96Y) revealed no 
apoptosis of the beta-cells in both models but decreased proliferation of the beta-cells 
associated with activation of ER stress and UPR, and diminished mTORC1 signalling 
(Balboa et al., 2018; Riahi et al., 2018). 
Wolfram syndrome 1 (WS1) is a rare autosomal-recessive neurodegenerative disorder 
associated with the development of juvenile-onset diabetes mellitus, optic atrophy and 
deafness (Barrett and Bundey, 1997; Cryns et al., 2003). The pathogenesis of WS1 ascribed 
to the loss-of-function mutation in the WFS1 gene that encodes wolframin, a transmembrane 
ER protein, the expression of which is triggered upon ER stress (Fonseca et al., 2005). A 
common polymorphism in WFS1 predisposes to T2D (Sandhu et al., 2007), although some 
WFS1 variants result in T1D in Japanese (Karasik et al., 1989; Awata et al., 2000). Mutation 
in Wfs1 gene in mice lead to the manifestation of diabetes due to activation of UPR, inhibition 
of intracellular calcium under glucose stimulation and disrupted cell cycle control (Riggs et 
al., 2005; Yamada et al., 2006). Wolframin 1 ablation in beta-cells leads to 
hyperphosphorylation of ATF6 and ER stress-induced beta-cell dysfunction and apoptosis 
(Fonseca et al., 2005). In line with the data from Wolfram syndrome postmortem pancreas, 
the increased expression of CHOP, ATF4, GRP78, and spXBP1 were observed in the beta-
cell deficient in Wolframin (Ishihara et al., 2004; Fonseca et al., 2010; Shang et al., 2014). 
Additionally, WS1 human induced pluripotent stem cells-derived neural progenitor cells and 
wolframin ablation in mice display impaired ER Ca2+ homeostasis, followed by initiation of 
the cysteine protease calpain and cell death (Lu et al., 2014).   
Wolcott-Rallison syndrome (WRS) is a rare genetic disease that caused by recessive 
homozygote mutations in the gene encoding eIF2α kinase 3 (EIF2AK3), known as PERK, 
and associated with neonatal insulin-deficient diabetes, defects in exocrine pancreas, hepatic 
steatosis, microcephaly, intellectual disability, skeletal dysplasia and growth retardation 
(Wolcott and Rallison, 1972; Stoss et al., 1982; Delepine et al., 2000; Senee et al., 2004). 
Likewise, embryonic inactivation of the Perk gene (Perk−/−) in mice leads to the loss of 
insulin-producing beta-cells and diabetes that is accompanied by failure of the exocrine 
pancreas, skeletal dysplasias in newborns and postnatal dwarfism, including deficient bone 
mineralization, osteoporosis, and abnormal compact bone development (Harding et al., 2001; 
Zhang et al., 2002). Pancreatic beta-cells in Perk−/− mice display ER distention, high rate of 
beta- cell apoptosis and decreased beta-cell proliferation. Additionally, these mice display 
excessive proinsulin synthesis (Harding et al., 2001), which is associated with increased 
proinsulin misfolding (Liu et al., 2005), suggesting ER overload and unresolved UPR 
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response leading to apoptosis. Studies of Gao et al. revealed that PERK ablation in the 
pancreases of either young adult or aged mice led to the development of diabetes associated 
with loss of islet beta-cells, indicating that PERK is required for maintaining glucose 
homeostasis in adult pancreas (Gao et al., 2012). PERK ablation resulted in ER distention 
and the accumulation of proinsulin and glucose transporter 2 (GLUT2) intracellularly. 
Moreover, PERK excision triggered the increased levels of GRP78 (both protein and mRNA) 
and Grp94 mRNA, and activation of two other remaining UPR branches – IRE1α and ATF6 
cascades and their downstream targets Xbp1 and JNK, leading to initiation of pro-apoptotic 
signaling cascade, while no increase in phosphorylated eIF2α was detected in PERK-excised 
islets (Gao et al., 2012). Taken together, PERK-mediated phosphorylation of eIF2 is 
essential for modulating proinsulin synthesis, folding and trafficking, and for ER quality 
control in pancreatic beta-cells (Gupta et al., 2009; Harding et al., 2012). 
In accordance with these observations, homozygous mice with a knock-in mutation in 
eIF2α (Ser51Ala) were lethal at neonatal stage with weak survival of the embryonic beta-cell 
(Scheuner et al., 2001). The mutation in Ser51Ala blocks stress-induced eIF2α translation 
attenuation and ATF4 transcriptional activity. Mice with the heterozygous state of eIF2α fed 
with the HFD displayed insulin resistance and functional alterations in beta-cells, although 
no signs of beta-cell failure were detected when mice were on the regular diet (Scheuner et 
al., 2005). Beta-cell dysfunction occurred as a result of misfolded proinsulin accumulation 
and ER dilation.  
P58IPK (DNAJC3) is ER stress-inducible Grp78 co-chaperon, which represses PERK 
pathway by inhibiting the activation of eIF2α signaling (Yan et al., 2002; van Huizen et al., 
2003). DNAJC3 loss-of-function mutations in humans associated with diabetes and several 
neurodegenerative aspects, including ataxia, upper-motor-neuron damage, peripheral 
neuropathy, hearing loss and cerebral atrophy (Synofzik et al., 2014). Ablation of p58IPK in 
mice results in the development of diabetes, characterized by beta-cell apoptosis and insulin 
deficiency associated with promoting of the PERK-CHOP signaling cascade (Ladiges et al., 
2005; Oyadomari et al., 2006; Laybutt et al., 2007). Interestingly, ablation of the Atf4 gene 
in mice did not affect either beta-cell function or survival, although diabetic Perk-/- mice 
displayed revoked ATF4 signals (Back et al., 2009). However, ATF4-deficient mice display 
abnormal bone formation, consequently leading to decreased bone mass (Yu et al., 2013), 
indicating that ATF4 is required for the skeletal homeostasis.  
Mice deficient in IRE1α develop widespread abnormalities, resulting in death after 12.5 
days of embryo development (Zhang et al., 2005). Specific ablation of IRE1α in the beta-
cells in mice during embryo development as well as deficiency of IRE1α particularly in the 
beta-cells of adult mice resulted in the manifestation of diabetes due to altered function of 
the beta-cells (Hassler et al., 2015; Tsuchiya et al., 2018). Ablation of IRE1α from both 
mouse beta-cells and hypothalamus led to obesity and insulin resistance with more severe 
phenotype than in control mice after exposure to HFD (Xu et al., 2014). These mice displayed 
reduced beta-cell mass caused by decreased beta-cell proliferation, possibly due to a decrease 
in spXBP1-dependent expression of cyclin D1 (Xu et al., 2014). Deficiency of Xbp1 
particularly in the beta-cells led to reduced proinsulin processing, insulin secretion, and beta-
cell proliferation as a result of IRE1hyperactivation (Lee et al., 2011). Mice heterozygous 
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to XBP1 developed impaired glucose tolerance and disrupted insulin signaling, when 
subjected to high fed diet, due to activation of PERK and JNK signaling (Ozcan et al., 2004). 
In accordance with the phenotype of IRE1α knockout mice, deficiency of both ATF6α 
and ATF6β in mice causes lethality by 8.5 days of embryo development, although a single 
knockout of each gene does not cause developmental defects (Wu et al., 2007; Yamamoto et 
al., 2007).  Later it was demonstrated that Atf6α-deficient mice display decreased insulin 
secretion under the conditions of HFD or when carrying the Akita Ins2 allele (Usui et al., 
2012). Specific ablation ATF6α in the beta-cells has no effect on its development and 
function (Engin et al., 2013). Human patients diagnosed with achromatopsia, a cone 
photoreceptor defect, are carriers of Atf6α “hypomorphic” mutations (Kohl et al., 2015). In 
contrast to PERK signaling, to date, there is no evidence of the implication of IRE1α or ATF6 
signaling pathways in human monogenic diabetes. 
Table 1. Summary of the phenotypes in mice, lacking UPR genes. Modified from (Hetz, 2012). 
Phenotype IRE1 Xbp1 Atf6α PERK ATF4 
Full knockout      
Embryonic lethal Yes Yes No* No No 
Postnatal death - - No Yes No 
Tissue specific effects      
Endocrine pancreas and 
insulin secretion alteration 
Yes Yes Yes** Yes No 
Altered bond formation - - - Yes Yes 
Impaired glucose 
metabolism 
Yes Yes - Yes No 
* - double knockout of ATF6α and ATF6β in mice causes embryonic lethality by 8.5 days of gestation 
(Wu et al., 2007; Yamamoto et al., 2007), ** - Atf6α-deficient mice display decreased insulin 
secretion under the conditions of HFD or when carrying the Akita Ins2 allele (Usui et al., 2012). 
3.6  Current and future therapies for the treatment of diabetes 
Currently, there is no cure for T1D and T2D and the treatment of diabetes depends on its 
pathophysiology and tailored towards preventing or delaying the manifestation of late disease 
complications, decrease death incidence, and preserve a good quality of life. In the case of 
T1D, the current treatment is the administration of insulin or insulin analogs, which has 
significantly reduced death rates associated with DM and its complications. Insulin injections 
could expose to a higher risk, including hypoglycemia and hyperglycemia periods, as well as 
causing distress to patients. Marked clinical success was also achieved with pancreatic islets 
transplantation from cadaveric donors as another possibility for T1D therapy (Bruni et al., 
2014). However, availability/selection of the donor and immunosuppression side effects 
persist as current complications of this therapy, as well as, recurrence of the disease. Human 
pluripotent stem cells are introduced as an alternative source of the pancreatic endocrine beta-
cells (Sneddon et al., 2018). Clinical trials (1/2 phase) are ongoing by Viacyte company 
aiming to treat T1D with human stem cell-derived islet cell implants 
(https://viacyte.com/archives/press-releases/center-for-beta-cell-therapy-in-diabetes-and-
viacyte-announce-start-of-european-clinical-trial-of-human-stem-cell-derived-implants-in-
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type-1-diabetes-patients). The choice of therapies for other types of diabetes include different 
antidiabetic drugs: 1) sulphonylureas and insulin secretagogues used in some PNDM, MODY 
and T2D (Kalra et al., 2018); 2) metformin for T2D (Song, 2016); 3) incretin mimetics, 
modified GLP-1 analogs like Exendin-4, Liraglutide and Exenatide LAR for T2D (Gupta, 
2013) and others. However, antidiabetic medications can lead to many potential side effects 
including hypoglycemia, nausea, upset stomach, weight gain, risk of liver disease, kidney 
complications and other. Insulin therapy may also be required for the treatment of T2D and 
monogenic forms of diabetes due to beta-cell death and insulin deficiency occurring with the 
disease progression. 
Regeneration of the beta-cell mass is thus a potential cure for insulin-dependent diabetes 
and under extensive investigation. Restoring the functional beta-cell mass in diabetes could 
be achieved by 1) enhancement of beta-cell replication (Dor et al., 2004), 2) promoting 
neogenesis of the beta-cell from progenitors within the pancreas (Xu et al., 2008) and 3) 
transdifferentiation of different pancreatic islet cells to functional beta cells (Thorel et al., 
2010). Several growth factors are known to regulate beta-cell proliferation (Table 2). Glucose 
infusion itself acts as a mitogen for beta-cells in rodents (Bernard et al., 1998; Alonso et al., 
2007). 
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Table 2. Summary of the major growth factors that are known to stimulate beta-cell proliferation. 
Growth factor Effects on beta-cell proliferation Reference 
Placental lactogen in vitro:  ↑ beta-cell proliferation 
in vivo: RipCre::PL1, ↑ beta-cell 
mass, ↑ beta-cell proliferation 
(Brelje et al., 1993; Vasavada 
et al., 2000; Cozar-Castellano 
et al., 2006) 
Prolactin in vitro: ↑ beta-cell proliferation 
in vivo: PrlR−/−, ↓ beta-cell mass 
(Brelje et al., 1993; Freemark 
et al., 2002) 
Growth hormone 
 
in vitro: ↑ beta-cell proliferation 
in vivo: GHR−/−, ↓ beta-cell mass, ↓ 
beta-cell proliferation 
(Brelje et al., 1993; Liu et al., 
2004) 
GLP-1 analogs (Exendin-4) in vitro: ↑ beta-cell proliferation 
in vivo: GLP1-Receptor-/-, no effect 
on beta-cell mass, 
Exendin-4 treatment, ↑ beta-cell 
proliferation, ↑ beta-cell mass 
(Scrocchi et al., 1996; Xu et 
al., 1999; Ling et al., 2001; 
Song et al., 2008) 
Insulin, Insulin-like growth 
factors 
in vitro: ↑ beta-cell proliferation 
in vivo: Rip-Cre::IRfl/fl,  ↓ beta-cell 
mass, 
RipCre::IGF-I Tg, ↑ beta-cell 
proliferation, no effect on beta-cell 
mass, beta-cell apoptosis and 
neogenesis 
Rip-IGF-II Tg, ↑ beta-cell mass 
IGF-II Tg, ↑ beta-cell proliferation, ↑ 
beta-cell mass, ↓ beta-cell apoptosis 
Pdx1Cre::IGF-Ifl/fl, ↑ beta-cell mass 
(Petrik et al., 1999; George et 
al., 2002; Paris et al., 2003; Lu 
et al., 2004; Otani et al., 2004) 
Epidermal growth factor 
(EGF) 
in vitro: modest effect 
in vivo: HIP-EGF Tg, ↑ beta-cell 
mass, ↑ beta-cell proliferation 
EGF-/-, no effect of beta-cell mass 
(Krakowski et al., 1999; 
Luetteke et al., 1999; Bernal-
Mizrachi et al., 2014) 
Platelet-derived growth 
factor (PDGF)  
in vitro: PDGF-AA, ↑ beta-cell 
proliferation 
in vivo: RIPCre:: PDGFRafl/fl, 
↓ beta-cell mass 
(Chen et al., 2011) 
Hepatocyte growth factor 
(HGF) 
in vitro: ↑ beta-cell proliferation 
in vivo: Rip-HGF Tg, ↑ beta-cell 
mass, ↑ beta-cell proliferation 
(Otonkoski et al., 1996; 
Garcia-Ocana et al., 2000; 
Garcia-Ocana et al., 2001; 
Cozar-Castellano et al., 2006) 
 
While several studies do not show neogenesis in adult mice either physiologically or after 
pancreatic duct ligation (Solar et al., 2009; Xiao et al., 2013), other studies identified 
pancreatic adult stem/progenitor cells in vivo (Xu et al., 2008). Duct cells were shown to 
promote differentiation of endocrine cells after the diphtheria toxin-induced cell death 
expressed under the Pdx1 promoter and after pancreatic duct ligation in mice and a partial 
pancreatectomy in rats (Criscimanna et al., 2011; Bonner-Weir et al., 2012). Islet neogenesis 
associated protein-pentadecapeptide (INGAPPP) were shown to promote neogenesis and 
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reverse streptozotocin-induced diabetes in mice (Bonner-Weir et al., 1993; Gu and 
Sarvetnick, 1993). Moreover, the overexpression of transforming growth factor-α (TGF-α) 
induced the expansion of Pdx1-expressing ductal cells, increasing islet neogenesis (Song et 
al., 1999).  
Several studies reported transdifferentiation of alpha- to beta-cells in response to 
pancreatic injury (Chung et al., 2010; Thorel et al., 2010). Conversion of alpha-cell to beta-
cells was also demonstrated under genetic reprogramming (Collombat et al., 2009).  The 
transgenic expression of Pdx1 in Ngn3 positive cells and the expression of Pax4 in alpha-
cells activated the regeneration of functional beta-cell mass by conversion of alpha-cells into 
beta-cells and protected from streptozotocin-induced diabetes in mice (Collombat et al., 
2009). Recent studies confirmed the transdifferentiation of alpha-cells to beta cells in a 
transgenic zebrafish model of beta cell ablation (Ye et al., 2015). Importantly, knockdown of 
the glucagon gene led to diminished regeneration of the beta-cells, indicating that glucagon 
is required for alpha-to-beta cell transdifferentiation (Ye et al., 2015). Studies of Chera et al. 
demonstrated that alpha-to-beta cell fate switching occurs from puberty through adulthood, 
and also in aged individuals (Chera et al., 2014). However, before puberty, the 
transdifferentiation arises form somatostatin-producing delta-cells, when the alpha-to-beta 
cell conversion is not active (Chera et al., 2014). 
Emerging evidence indicates that beta-cell regeneration can be implemented by 
targeting ER stress and UPR in diabetes. Several chemical compounds and drugs were 
demonstrated to target UPR by 1) direct interaction with the components of the UPR, 2) 
reduction of ER stress, 3) suppression of protein degradation, 4) promoting antioxidant 
activity and 5) regulation of ER calcium signaling (Hetz et al., 2013). Chemical chaperones 
such as 4-phenyl butyric acid (PBA) and taurine-conjugated ursodeoxycholic acid (TUDCA) 
was shown to be effective in targeting the UPR and alleviating ER stress in various animal 
models.  PBA and TUDCA restored glucose metabolism and insulin sensitivity in ob/ob mice 
by diminishing the activity of PERK and IRE1α/JNK signaling, indicating their potential use 
for the treatment of T2D (Ozcan et al., 2006).  
Studies with the NOD mice also revealed beneficial effect of TUDCA, including 
reduced insulitis, decreased beta-cell death, improved insulin secretion and normalized 
expression of ATF6 and Xbp1(Engin et al., 2013). Furthermore, TUDCA is underway in a 
clinical trial of recent-onset T1D (https://clinicaltrials.gov/ct2/show/NCT02218619). Oral 
administration of PBA to humans was suggested to reduce insulin resistance in T2D patients 
(Xiao et al., 2011).  
Several other small molecules that diminish the activity of UPR in diabetic models have 
been identified. The ability of Exendin-4 to protect from ER stress-induced beta-cells 
apoptosis in vitro were shown in several studies (Yusta et al., 2006; Cunha et al., 2009; Oh 
et al., 2013). Additionally, Exendin-4 reverse ER stress-mediated beta-cell death in diabetic 
Akita and db/db mouse model (Yusta et al., 2006; Yamane et al., 2011). Therefore, Exendin-
4 is a potential treatment for T1D and other monogenic types of diabetes associated with ER 
stress. 
Morita and colleagues identified that targeting the interaction of cytosolic ABL kinases 
with IRE1α could be a potential target for the treatment of autoimmune diabetes (Morita et 
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al., 2017). The ABL-IRE1α axis was shown to potentiate apoptosis during ER stress and anti-
cancer drug imatinib was able to decrease beta-cell death by diminishing the interaction of 
ABL with IRE1α and preventing the proapoptotic UPR thereby reversing diabetes in NOD 
mice (Morita et al., 2017). Moreover, KIRAs that selectively inhibit kinase/RNase activity 
of IRE1α promoted recovery of the beta-cells in the NOD and diabetic Akita mouse models 
(Morita et al., 2017). Thus, current study holds promise for imatinib and KIRAs to be used 
for the treatment of diabetes associated with ER stress. 
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AIMS OF THE STUDY 
This study was designed to elucidate the biological functions of MANF in vivo by careful 
characterization of MANF conventional and conditional knockout mice phenotypes. 
The specific aims were: 
- To study in detail the expression of MANF in mouse tissues involved in metabolic 
homeostasis  
- To study CDNF expression in mouse tissues 
- To characterize the phenotypes of MANF-deficient mice 
- To study the signaling pathways affected by MANF deficiency in pancreatic beta-
cells 
- To investigate  the exogenous effect of MANF protein on mouse pancreatic beta-cells  
in vitro   
- To assess the  effect of MANF-overexpression in mouse beta-cells on experimentally 
induced T1D diabetes in vivo 
- To implement a new fast and fully automated graphical software for the histological 
analysis of mouse pancreas based on the Deep Convolutional Neural Networks 
technique 
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MATERIALS AND METHODS 
The main methods used by the thesis author are presented in the Table 3. Detailed 
descriptions of the materials and methods can be found in the original publications and 
manuscripts and their supplements.  
Table 3. Methods used in the studies. 
Methods Used in The author contributed 
to the experiments 
Mice and physiological tests in vivo   
Generation of Manf-/- and Manffl/fl mice II, III  
Mice genotyping I, II, III + 
Glucose tolerance test, insulin tolerance test, and glucose 
challenge test followed by analysis of blood samples 
II, III + 
Comprehensive Laboratory Animal Monitoring System 
(CLAMS) 
II  
Molecular biology experiments   
DNA, RNA and protein isolation I, II, III + 
cDNA synthesis I, II, III + 
Real Time PCR and Quantitative PCR I, II, III + 
Immunological methods   
Western blotting analysis II, III + 
Immunohistochemistry I, II, III, IV + 
Pancreatic islet isolation II, III + 
Enzyme-linked immunosorbent assay (ELISA)   
Insulin ELISA from sera and tissue culture media II, III + 
Mouse MANF ELISA from tissue  I + 
Mouse CDNF ELISA from tissue  I + 
Cell culture experiments   
Pancreatic islet isolation II, III + 
Cell lines and primary cell culture  II, III + 
In vitro experiments with primary cells  II, III + 
In vitro insulin release experiments II, III + 
Cytospins II, III + 
Immunocytochemistry III + 
Subcellular localization analysis III + 
Animal models   
Multiple low-dose streptozotocin-induced mouse model 
of diabetes type 1 
II + 
Pancreatic intraductal delivery of AAV6-MANF II + 
Imaging   
One-photon microscopy imaging I, II, III + 
3D HISTECH Panoramic 250 FLASH II digital slide 
scanner 
I, III, IV  
Confocal microscopy III + 
Electron microscopy III  
Quantitative image analysis I, II, III, IV + 
Statistical analysis I, II, III, IV + 
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Unpublished methods 
MIN6 cell culture and immunocytochemistry 
Mouse insulinoma cell line (MIN6) was cultured in the Dulbecco’s modified Eagle’s medium 
(DMEM, Sigma) media supplemented with 10% fetal bovine serum, 70µM β-
mercaptoethanol and antibiotics in humidified 5% CO2 at 37ᵒC. For immunocytochemistry, 
MIN6 cells were cultured on the coverslips plated with poly-L-lysine and fixed in 4% 
paraformaldehyde for 15 minutes at room temperature. The cells were stained with antibodies 
to MANF (1:1000, 310-100, Icosagen), insulin (1:200, ab7842, Abcam), GRP78 (1:500, sc-
1051, Santa Cruz Biotechnology), PDI (1:200, ADI-SPP-891-F, Enzo/AH Diagnostics) and 
GM130 (1:200, 610823, BD Transduction Laboratories), following by the labeling with 
Alexa Fluor® 488 or 568  secondary antibodies (1:400, Molecular Probes, Life 
Technologies) and DAPI (Vectorshield, Vector laboratories). 
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RESULTS AND DISCUSSION 
4.  MANF and CDNF expression in mouse tissues  
Neurotrophic factors are growth factors that not only promote the survival and regeneration 
of the neurons but often also act outside the nervous system. MANF and CDNF family of the 
growth factors differ structurally and functionally from the other classical neurotrophic factor 
families. The protective and restorative properties of MANF and CDNF have been 
documented for both neuronal and non-neuronal cells. A better understanding of MANF and 
CDNF tissue distributions could provide important clues to their roles in CNS and peripheral 
target tissues, which in turn could be utilized to discover the most promising indications for 
these growth factors.  Expression of MANF and CDNF was previously characterized (chapter 
1.2). However, a full-scale report on the analysis of MANF and CDNF expression pattern in 
mouse embryonic and adult tissues have not been published. Therefore, an expression study 
using different approaches like IHC, QPCR and in-house build ELISA was justified. The 
comparison of antibody immunoreactivity in wild-type tissues with knockout animals, where 
the protein of interest has been silenced by genetic modification, is the most stringent control 
for antibody specificity. To ensure antibody sensitivity and specificity in our studies, we 
validated MANF and CDNF antibodies by using Manf and Cdnf knockout tissue as negative 
controls.  
4.1  MANF expression during embryo development 
(Original publication I and III) 
We studied MANF expression in mouse embryos at different developmental stages by LacZ 
staining of heterozygous Manf+/- embryos expressing the -galactosidase reporter gene under 
the Manf promoter and by IHC with MANF antibodies of wild-type (WT) Manf+/+ embryos. 
In the current study, we demonstrated by LacZ staining for the first time that MANF is 
expressed already in the embryonic stem cells (Supplementary Figure 1A, I). At E7.5 LacZ 
positive staining was detected in all germ layers, revealing that MANF is important for the 
development of various tissues derived from all three germ layers. Similarly to LacZ staining, 
immunohistochemical analysis revealed MANF immunoreactivity in the developing E9.5 
mouse embryo (Figure 1E-H, I). MANF expression was observed in the forebrain, midbrain 
and hindbrain parts of the neural tube. Additionally, MANF positive expression was found 
in the somites (Figure 1G, I), structures that are needed for the development of the dermis, 
skeletal muscles, and vertebrae. We also detected MANF immuno-reactive cells in the 
developing heart (Figure 1E, I). 
Consistent with the findings of ISH done on E12.5 mouse embryos (Lindholm et al., 
2008), we observed widespread expression of MANF at E13.5 in mouse embryos (Figure 1I-
Y, Supplementary Figure1E-J, I), when most of the organs begin to differentiate. MANF 
expression was observed in the neocortex (Figure 1K, I), striatum (Figure 1M, I), midbrain 
(Figure 1N, I), developing hypothalamus parts (Figure 1O-P, I), spinal cord, choroid plexus 
(Figure 1L, I), the lumen of Rathke’s pouch (Figure 1Q, I), that give rise to the anterior 
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pituitary gland, vestibulocochlear ganglion (Figure 1R, I), trigeminal ganglia and dorsal root 
ganglia (Figure 1S-T, I).  MANF positive cells were also observed in the developing 
peripheral tissues such as heart (Figure 1U, I), lung (Figure 1V, I), liver (Figure 1X, I), 
intestine (Figure 1W, I), and pancreas (Figure 1Y, I, Figure 1, III). 
Taken together, we observed the ubiquitous expression of MANF in most mouse tissues 
during the embryonic development, suggesting an essential role for MANF during 
embryogenesis.  
4.2  MANF expression in the CNS and PNS  
(Original publication I) 
In the current work, we presented a comprehensive study of MANF expression in the mouse 
brain, using MANF antibodies validated by using Manf-/- tissue as negative controls. 
Previously, MANF expression within the CNS was studied in the embryonic heads (E17, 
E18.5) or whole embryos (E13, 17) and brains at P1, P10, and adult in the mouse species 
(Lindholm et al., 2008; Tseng et al., 2017). On top of that, a recent study by Wang et al. 
identified that MANF is expressed in the developing rat brain and it was suggested that 
MANF expression declines with the rat brain maturation (Wang et al., 2014).  
 Consistent with previous studies (Lindholm et al., 2008; Wang et al., 2014), we 
observed a positive MANF expression in different brain areas at P14 (Figure 
3,Supplementary Figure 2, I), including cerebral and prefrontal cortex,  olfactory bulbs with 
high levels of MANF in mitral cell layer and anterior olfactory nucleus (Supplementary 
Figure 2A-B, I), striatum (Supplementary Figure 2D, I), subventricular zone, thalamus 
(Supplementary Figure 2I, I), CA1-CA3 hippocampal pyramidal neurons as well as in 
dentate gyrus (Supplementary Figure 2E-G, I), choroid plexus (Supplementary Figure 2H, 
I), substance nigra (Supplementary Figure 2J, I), cerebellum (Supplementary Figure 2K, I). 
MANF expression was found in the neuronal subpopulation but not in glial cells studied by 
IHC (Supplementary Figure 2Q-S, T-U, I). MANF positive cells were colocalized with TH-
positive dopamine neurons in the substantia nigra as also shown by Lindholm et al. 
(Supplementary Figure 2W-Y, I) (Lindholm et al., 2008). MANF expression was also found 
in the calbindin-positive cell bodies of cerebellar Purkinje cells and their dendrites in 
agreement with an earlier report (Supplementary Figure 2Z-BB, I)  (Yang et al., 2014a). 
Notably, we identified that MANF is highly expressed in the cells of various CNS 
centers containing glucose sensing cells, including mesocortical/mesolimbic dopamine 
system, different areas of hypothalamus and brainstem structures of the mouse brain at P14 
( Figure 3, Supplementary Figure2, I).  
The hypothalamus regulates food intake, energy balance, and endocrine systems through 
the pituitary gland (Kelberman et al., 2009; Roh et al., 2016). Within the hypothalamus, 
abundant expression of MANF was detected in the medial preoptic area (Figure 3C, I), 
paraventricular hypothalamic nuclei (Figure 3D, I), supraoptic nuclei (Figure 3E, I), 
dorsomedial nucleus (Figure 3F, I), arcuate hypothalamic nucleui and median eminence 
(Figure 3G, I) and ventromedial hypothalamic nuclei (Figure 2H, I). Furthermore, we 
identified that MANF positive cells are co-expressed with oxytocin (Figure 3S-U, I) and 
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vasopressin (Figure 3V-X, I) positive cells in paraventricular hypothalamic nuclei and 
supraoptic nuclei parts of the hypothalamus.  
Inside the brain stem structures, which are also known for the regulation of food intake, 
we identified high levels of MANF in the locus coeruleus nucleus (Figure 3M, I), dorsal 
nucleus of the vagus nerve (Figure 3R, I), rostral ventrolateral medulla (Figure 3O, I) and 
low levels in parabrachial nucleus (Figure 3N, I), area postrema (Figure 3P, I), sensory 
nucleus of the solitary tract (Figure 3Q, I). Additionally, MANF expression is detected in 
circumventricular organs, such as subcommissural organ (Supplementary Figure 2L, I), AP. 
We identified that MANF is co-expressed with acetylcholinesterase positive motor neurons 
of the dorsal nucleus of the vagus nerve part of the mouse brain (Figure 2Y-AA, I), which 
regulates secretion and motility within the gastrointestinal tract, and secretion within the 
pancreas (Mussa and Verberne, 2013). 
Additionally, we found MANF expression within the mesolimbic and mesocortical 
dopaminergic pathways that regulate hedonic feeding. Moderate expression of MANF was 
observed in the medial prefrontal cortex (Figure 3I, I), paraventricular nucleus of the 
thalamus (Figure 3K, I), nucleus accumbens (Figure 3J, I) and ventral tegmental area (Figure 
2L, I). We identified that MANF is co-expressed with all TH-positive dopamine neurons in 
the ventral tegmental area (Figure 3BB-DD, I).  
Descending neuronal projections from hypothalamus via brainstem structures to the 
intermediolateral column of the spinal cord connect with the autonomic nervous system are 
known to regulating heart rate, respiration, brown adipose tissue (BAT)/thermogenesis, and 
white adipose tissue (WAT)/energy state. We identified MANF expression in the adult mouse 
spinal cord (Figure 4A-E, I). MANF positive cells were detected within the grey matter in 
the glial cells and within the white matter in the myelinated axons. MANF expression was 
observed in neuronal subpopulations of the dorsal and ventral horns of the mouse spinal cord. 
Especially strong expression of MANF was detected in the motor neurons and their dendrites 
immuno-labeled with acetylcholinesterase and neuroendocrine PGP9.5 markers (Figure 4B, 
4F-H, 4I-K, I).  
Additionally, we observed a high intensity of MANF staining within the peripheral 
nervous system. Strong MANF expression was detected in the neuronal bodies of the dorsal 
root ganglion (Figure 4L-N, 4O-Q, 4R-T, I), which is known for its regulation of 
thermogenesis in BAT (Ryu et al., 2015). MANF expression was also high in the neurons of 
celiac ganglia (Figure 4U-W, 4X-Z, 4AA-CC, I), a component of the autonomic nervous 
system that regulates functions the digestive tract, liver, and pancreas. 
Initially, MANF was identified as a potent factor for dopamine neurons and previous 
studies pointed towards MANF protective and restorative effects in different neuronal 
populations in vitro and in vivo mainly focusing on neurodegenerative diseases. Herein, we 
detected MANF expression in the CNS centers that are responsible for the homeostatic and 
hedonic regulation, suggesting widespread roles for MANF in regulating energy homeostasis 
by controlling food intake and glucose metabolism in peripheral tissues, as well as metabolic 
function, thermogenesis, heart rate, respiration and digestion. Lately, MANF was shown to 
influence food intake and body weight by regulating insulin signaling in the mouse 
hypothalamus (Yang et al., 2017) (chapter 1.4.4). Overexpression or knockdown of 
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hypothalamic MANF resulted in hyperphagia or hypophagia, respectively. Still, the role of 
the hypothalamic MANF expression in the control of energy balance remains unclear as 
randomly fed neuron-specific NestinCre::Manffl/fl mice do not show any signs of impaired 
insulin signaling (chapter 5.3.3), (Lindahl et al., 2014)(Pakarinen et al., manuscript). 
Moreover, the role of MANF in the mesocortical/mesolimbic dopamine system, brainstem 
structures, spinal cord, and autonomic nervous system requires further investigation.  
4.3  MANF expression in endocrine tissues  
(Original publication I) 
Results of previous work revealed that MANF is expressed at high level in secretory tissues 
(Lindholm et al., 2008). Therefore, we carefully investigated MANF expression in the mouse 
endocrine system including the hypothalamus, pituitary gland, pineal body, thyroid, and 
parathyroid glands, adrenal glands, pancreas and the reproductive organs (ovaries and testes). 
The endocrine system controls growth and developmental processes, homeostasis, 
metabolism, reproduction, and response to stress and injury stimuli. High level of MANF 
expression was observed in mouse pituitary gland, especially strong levels were detected in 
adenohypophysis and in the intermediate lobe (Figure 5A-C, I). MANF positive cells were 
also found within the neurohypophysis (Figure 5D, I). The pituitary gland is a central gland 
in the endocrine system because it controls the functions of other hormonal glands and 
regulates growth, reproduction, endocrine functioning and functions to convey signals from 
the hypothalamus to various organs  (Kelberman et al., 2009). The adenohypophysis consists 
of five types of cells that secrete different hormones: somatotropes secrete growth hormone 
(GH), lactotropes prolactin (PRL), gonadotropes follicle stimulating hormone (FSH) and 
luteinizing hormone (LH), corticotropes adrenocorticotropic hormone (ACTH), and 
thyrotropes thyroid-stimulating hormone (TSH) (Ooi et al., 2004). We identified the co-
localization of MANF expressing cells with GH and PRL secreting cells in the anterior 
pituitary gland at 6 weeks of age (Figure 6 G-I, 6J-L, I). The role of MANF in mouse 
adenohypophyses will be discussed in chapter 5.2 and 5.4. The mouse intermediate lobe of 
the pituitary gland is composed of melanotropes, which produce and secrete an α-
melanocyte-stimulating hormone (α-MSH), a central regulator of energy homeostasis, and β-
endorphin. Neurohypophysis mainly consists of neuronal projections from the hypothalamus 
and is responsible for the secretion of vasopressin and oxytocin to the bloodstream.  
We also found strong MANF immunoreactivity in both thyroid and parathyroid glands 
(Figure 5E-G, I). MANF was highly expressed by the thyroid follicular cells responsible for 
the synthesis of thyroxine (T4), triiodothyronine (T3) as well as in calcitonin positive C-cells 
(Figure 5H-J, I) in the thyroid gland.  MANF was also high in parathyroid (PTH) cells. In 
the adrenal gland, MANF was expressed both in the cortex and at lower levels in the medulla 
(Figure 5K, I). We demonstrated that MANF was co-expressed with TH positive chromaffin 
cells in the medulla (Figure 5L-N, I) that are responsible for the synthesis and release of 
catecholamines, adrenaline, and noradrenaline, in response to stress. 
We observed strong immunoreactivity of MANF in the mouse pancreas. The detailed 
analysis of MANF expression in the pancreas will be discussed in chapter 4.2.1. 
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Next, we analyzed MANF expression in the mouse reproductive system. We observed 
MANF expression in the female mouse ovaries and ampullas (Figure 5O-Q, I). Notably, 
exceptionally high expression of MANF was observed in granulosa cells (Figure 5P, I), 
which surround the oocyte in the ovary. Additionally, we detected MANF expression in male 
gonads, specifically in the seminiferous tubules as also previously reported by Lindholm et 
al. (Figure 5R, I) (Lindholm et al., 2008). Hence, MANF expression in mouse tissues of the 
reproductive system might be needed for proper fertility.   
To conclude, we detected extremely high level of MANF expression within the secretory 
cells of the mouse endocrine system, suggesting that MANF has important functions within 
cells with high production and secretion of various proteins and hormones.  In addition, , the 
pattern of high MANF expression within the endocrine axes such as hypothalamic–pituitary–
thyroid, hypothalamic–pituitary–adrenal/interrenal and  hypothalamic–pituitary–gonadal 
axes suggest that MANF plays a crucial role in hormonal regulation thereby modulating 
energy metabolism, growth, development, stress responses and reproductive processes.  
Consequently, our studies on MANF-deficient mice revealed important roles for MANF in 
the mouse pancreas and pituitary gland (Chapter 5.2). Previous studies revealed that MANF 
deficiency in C. elegans led to fewer descendants, providing evidence that MANF is required 
for proper function of reproductive system in C. elegans (chapter 1.4.3) (Richman et al., 
2018). Interestingly, increased expression of MANF was observed in the mouse oocytes after 
in vitro maturation (Wang et al., 2011), possibly in response to stress due to the procedure. 
However, more research is required to clarify the functions of MANF in other type of 
endocrine tissues.  
4.3.1  MANF expression in the mouse pancreas 
(Original publication I, II, III) 
Pancreas consists of exocrine tissues and dispersed endocrine islets of Langerhans. The 
exocrine part is composed of the ductal and acinar cells, which synthesize and secrete 
digestive enzymes such as carboxypeptidase, amylase, and lipase into the pancreatic duct that 
connects to the duodenum. Islets of Langerhans consist of several endocrine cell types each 
secreting different hormones: alpha-cells, beta-cells, delta-cells, and pancreatic polypeptide 
(PP)-cells, which are responsible for the production and secretion of glucagon, insulin, 
somatostatin, and pancreatic polypeptide respectively. The majority of the cells within the 
endocrine islets are the beta-cells, which occupy 70–80% (Brissova et al., 2005) of the islet 
and which by secreting insulin into the blood stream regulate the blood glucose levels. 
High levels of MANF was observed in the developing pancreas during differentiation 
processes in E13.5 mouse embryo by IHC and confirmed by positive LacZ staining and IHC 
in E12.5 (Figure 1Y, I, Figure 1A, Supplementary Figure 1.1A, Supplementary Figure 2.2K, 
2.2O, III). We also observed MANF expression in the pancreatic islets and exocrine acinar 
cells at E18.5, P1, P3 and P14 addressed by IHC (Supplementary Figure 2.2L, 2.2P, 2.2M, 
2.2Q, 2.3A, 2.3D, III). Our studies revealed that in comparison with other mouse tissues, the 
highest expression levels of MANF protein and mRNA were found in the endocrine islets 
and pancreatic exocrine acinar cells of the adult mouse pancreas analyzed by western blotting 
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(Supplementary Figure 4A-B, II, Figure1 B, Supplementary Figure 1.1C, III). MANF 
mRNA and protein in mouse pancreatic islets and exocrine tissue were relatively the same 
(Figure 1E, 1F, III). Similarly to mouse pancreas, we also identified immunoreactivity of 
MANF in the endocrine islets and exocrine acinar cells of the human pancreas 
(Supplementary Figure 4G-I, II). Importantly, double-IHC on pancreatic sections from adult 
mice, revealed that MANF was mainly localized in the beta-cells (Figure 1G-I, III), less in 
delta-cells (Figure 1K-M, III), but was not detected in alpha- or PP-cells (Figure 1O-Q, 1S-
U, III). In support to our data, MANF expression was observed in beta-cells and also delta-
cells but not in alpha-cells in human pancreas (Hakonen et al., 2018), although human MANF 
mRNA was observed in both beta-cells and alpha-cells in similar levels (Segerstolpe et al., 
2016). This result suggest that translation of MANF mRNA does not occur in alpha-cells. 
PDX1 is a key regulator for pancreatic development and beta-cell maturation (Fujimoto 
and Polonsky, 2009). During pancreas development, PDX1 marks the progenitors of all 
exocrine and endocrine cell types at E8.5-E9.5 in mouse embryo (Ohlsson et al., 1993). In 
adult pancreas, PDX1 expression becomes restricted to the beta-cells (Ashizawa et al., 2004). 
GLUT2 is expressed at the cell membrane in the mouse beta-cells and required for the insulin 
secretion stimulated by glucose (Thorens, 2015). In the mouse islets MANF positive cells 
co-expressed with pancreatic and duodenal homeobox 1 (PDX1) in the nucleus 
(Supplementary Figure 1.1H-J, III) as well as GLUT2 (Supplementary Figure 1.1E-G, III), 
proving that indeed MANF is expressed in beta-cells. 
The in vivo role of MANF in the mouse pancreas will be discussed in chapter 5.2. 
4.3.2  Cellular localization of MANF in the mouse primary beta-cells and MIN6 cell line  
(Original publication III and unpublished results) 
Previous studies revealed MANF localization in the ER of the neurons and immortalized cell 
lines (Glembotski et al., 2012; Henderson et al., 2013; Matlik et al., 2015). 
In order to investigate the subcellular localization of MANF in the beta-cells, we 
performed confocal analysis of the mouse primary islets cells stained with insulin, PDI 
(protein disulfide isomerase, a marker for ER), GM130 (a marker for cis-Golgi), GRP78, and 
MANF. We observed robust co-localization of MANF with insulin in the ER (Figure 1W, 
1Y, Supplementary Figure 1.1 K-S, 1.1 M-U, III), a limited co-localization of MANF with 
GRP78 (Figure 1Z, Supplementary Figure 1.1 N-V, III) and complete separation of MANF 
from Golgi (Figure 1X, Supplementary Figure 1.1 L-T, III) in unstressed cells based on the 
Mander’s and Pearson correlation coefficients (Table 2, III). Consistent with the results on 
primary beta-cells, we observed co-expression of MANF with PDI as a marker for ER and 
GRP78, partial co-expression with insulin and segregation with GM130 used as a marker for 
Golgi in mouse insulinoma MIN6 cell line (Figure 4). Furthermore, our collaborative studies 
confirmed MANF localization in the ER of the human beta-cell line EndoC-H1 (Hakonen 
et al., 2018). Taken together, the results confirm that MANF is localized in the ER of both 
mouse and human beta-cells.  However, MANF is secreted from human beta-cell line EndoC-
H1upon cytokine treatment (Hakonen et al., 2018), suggesting that secretion of MANF is 
destined via the Golgi apparatus transport. 
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Figure 4. Representative microscopy images of MIN6 cell line labeled with MANF (red) and co-
stained with PDI (ER marker, green), GM130 (Golgi marker, green), GRP78 (green) or insulin 
(green) antibodies. Scale bar, 20 µm.  
4.4  MANF expression in other tissues  
(Original publication I) 
Within the organs with exocrine functions, strong MANF expression was detected in all parts 
of mouse salivary gland including sublingual gland, parotid gland, and submandibular gland 
(Supplementary Figure 4A-C , I). Notably, MANF was detected in the mucous acini and 
serous acini of the submandibular gland and secretory acini of the parotid gland. Variable 
expression of MANF was detected in mouse lungs (Supplementary Figure 4D, I), which 
consists of epithelial, endothelial and hematopoietic cells. High expression of MANF was 
observed in tracheal and esophagus epithelium cells (Supplementary Figure 4E, 4F, I). In 
mouse skin, we observed MANF immunoreactivityin the epithelium, sebaceous glands and 
the cells of the dermis (Supplementary Figure 4G, I). Taken together, strong MANF 
expression were observed in the organs with exocrine functions and epithelial cells of several 
tissues, suggesting that MANF regulates secretory functions and thus might promote 
epithelial barrier function of these tissues.  
In the liver, low MANF expression was detected by IHC in hepatocytes (Supplementary 
Figure 7J, I). In the kidney, high immunoreactivityof MANF was observed in the cells of the 
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juxtaglomerular apparatus compared with low levels in the tubules (Supplementary Figure 
7G-I, I). These results suggest possible roles for MANF in renin–angiotensin–aldosterone 
hormonal system that regulates blood pressure and fluid and electrolyte balance in the body. 
We also observed MANF expression throughout the gastrointestinal tract (GI). 
Specifically, MANF positive immunoreactivity was identified in epithelial cells of the villi 
in the duodenum (Supplementary Figure 4H, I). The high intensity of MANF staining was 
observed in certain cells including enterocytes, mucus secreting goblet cells, and crypt Paneth 
cells (Supplementary Figure 4I-K, 4L-N, 4O-Q, I). So, MANF might have a role in intestinal 
epithelial barrier function and antigen uptake. 
Previous studies identified MANF protective role for cardiomyocytes simulated 
ischemia and heart ischemia (chapter 1.3.4) (Tadimalla et al., 2008; Glembotski et al., 2012). 
Moreover, it demonstrated increased MANF expression in the mouse heart after ischemia 
(Tadimalla et al., 2008). We found only a low number of MANF immune-reactive cells in 
cardiac muscle and atrium tissue of the mouse heart (Supplementary Figure 5A-C, I), and in 
muscle (Supplementary Figure 5E, I), suggesting that MANF might not have a direct function 
in these tissues, but acting in a stress-induced conditions. 
 MANF positive cells were also detected in epicardial adipose tissue (Supplementary 
Figure 5D, I). In addition, we detected MANF immune-reactive cells in adipocytes of WAT 
(Supplementary Figure 5F, I) and BAT (Supplementary Figure 5G, I). These results together 
with the previous finding (chapter 4.2, MANF expression in CNS and PNS) further supports 
that MANF might be important for the highly metabolic cells that regulate thermogenesis 
and modulates energy state in mice. 
We also detected MANF expression within the mouse lymphatic system including 
spleen, thymus, lymph node, and intestinal lymphatic tissue - Peyer's patches, which are 
known for its regulation of the adaptive and innate immune system. We observed MANF 
expression mainly within the red pulp and marginal-zone in the spleen in agreement with an 
earlier report (Supplementary Figure 6A-B, I) (Liu et al., 2015a). Within the thymus, MANF 
expression was mainly detected in the medulla (Supplementary Figure 6C-D, I). We also 
detected MANF positive cells in mouse lymph node (Supplementary Figure 6E-F, I) and 
small lymphatic tissue of the intestine Peyer's patch (Supplementary Figure 6G-H, I). 
Expression of MANF within the lymphatic system implicates a possible function of MANF 
in the immune system. Certainly, previous studies documented anti-inflammatory properties 
of MANF (chapter 1.3.3). On the other hand, the immune cells are highly secretory cells that 
have a high demand for folding of the proteins in the ER (Grootjans et al., 2016). Hence, 
MANF expression in lymphatic tissues could be required for maintaining the ER homeostasis 
in the immune cells. However, more research is required to investigate the role of MANF 
within the lymphatic system. 
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Table 3. Summary table of MANF expression in adult mouse tissues by different techniques. 
Mouse tissue Relative Manf 
mRNA level/β-actin 
MANF protein 
levels, ng/mg total 
protein by ELISA 
IHC MANF 
Pituitary gland ++++ ++++ +++++ 
Thyroid gland ++ ++ +++++ 
Adrenal gland ++ ++ ++++ 
Pancreatic islets +++++ not analyzed +++++ 
Pancreatic exocrine tissue +++++ not analyzed +++++ 
Testis ++++ +++++ +++++ 
Ovary +++ ++ +++ 
Brain + +++ +++ 
Thymus + + ++ 
Lung ++ not analyzed + 
Heart ++ + + 
Liver +++ ++++ +++ 
Salivary gland +++ ++++ +++++ 
Kidney + ++ + 
Spleen + ++ + 
Duodenum +++ not analyzed +++ 
Jejunum +++ not analyzed not analyzed 
Ileum ++ not analyzed not analyzed 
Colon ++ not analyzed not analyzed 
Muscle ++ + + 
Brown adipose tissue (BAT) not analyzed +++ ++ 
White adipose tissue (WAT) not analyzed + + 
++++ - very strong expression, +++ - strong expression, ++ - moderate expression, + - low expression 
4.5  CDNF expression in mouse tissues 
(Original publication I) 
MANF and CDNF are homologous proteins with seemingly distinct functions (Lindahl et al., 
2017). Therefore we wanted to know whether they are differently expressed in mouse tissues 
by extensive comparative analysis of mRNA and protein expression using qPCR and ELISA.  
So far, we were not able to identify an anti-CDNF antibody that would specifically 
recognize endogenous CDNF in mouse tissues by IHC. However, in this study, we analyzed 
CDNF expression in mouse tissues by qPCR and in-house developed CDNF ELISA. 
Consistent with previous studies, we identified that the levels of CDNF protein in mouse 
tissues are significantly lower compared to the levels of MANF protein (Table 4). High Cdnf 
mRNA levels were observed in mouse testis, pituitary gland and exocrine tissue of the 
pancreas, heart, and muscle compared to relatively low levels in the rest of analyzed tissues 
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(Figure 2C, I). CDNF protein is highly expressed in mouse heart, muscle, testis, and BAT 
(Figure 2D, I). Moderate CDNF protein levels were observed in the pituitary gland, adrenal 
gland, kidney, ovary, brain, thymus and WAT compared with low levels in pancreas, liver, 
salivary gland, and spleen (Figure 2D, I). 
These differences in expression patterns indicate to partly distinct roles for MANF and 
CDNF in vivo. In support of this hypothesis, opposite to phenotypes of Manf-/- mice, we did 
not observe apparent defects in growth, diabetes or the lifespan of Cdnf−/− conventional 
knockout mice (Lindahl et al., unpublished data). 
Table 4. Comparison of MANF and CDNF protein expression in mouse tissues using ELISA.  
Mouse tissue MANF protein levels, ng/mg 
total protein 
CDNF protein levels, ng/mg 
total protein 
Pituitary gland 338.6±3.91  1.26±0.19 
Thyroid gland 139.0±3.37  30.64±1.66 
Adrenal gland 134.2±3.75  2.55±0.47 
Pancreas 894.1±9.41  0.09±0.03 
Testis 1169.5±9.16 / 10.77±0.84 
Ovary 165.1±3.4  0.77±0.18 
Brain 247.6±2.79  0.76±0.19 
Thymus 123.4±2.03  0.89±0.23 
Lung not analyzed not analyzed 
Heart 38.5±0.99  18.84±0.84 
Liver 375.7±4.65  0.12±0.09 
Salivary gland 320.1±5.97  0.28±0.14 
Kidney 176.8±1.38  1.42±0.21 
Spleen 187.6±0.8  0.3±0.09 
Duodenum not analyzed not analyzed 
Jejunum not analyzed not analyzed 
Ileum not analyzed not analyzed 
Colon not analyzed not analyzed 
Muscle 81.8±1.67  19.22±0.86 
Brown adipose tissue (BAT) 198.7±2.63  11.91±0.47 
White adipose tissue (WAT) 66.6±2.63  1.54±0.3 
4.6  Upregulation of MANF and CDNF expression in ER stress conditions in vivo  
4.6.1  MANF expression is upregulated in the beta-cells of diabetic mice 
(Original publication III) 
Previous studies identified increased levels of MANF mRNA and protein in the beta-cells of 
Ins2Akita mice, where misfolded proinsulin accumulates in the ER thereby triggering initiation 
45 
of ER stress and UPR resulting in the apoptosis of beta-cells (Oyadomari et al., 2002a; 
Oyadomari et al., 2002b; Mizobuchi et al., 2007; Balboa et al., 2018; Riahi et al., 2018). Islets 
isolated from pre-diabetic NOD mice display enhanced Manf mRNA and activation of the 
UPR that was found to precede the beta-cell death (Tersey et al., 2012; Morita et al., 2017). 
In agreement with this data, we identified increased MANF expression in the beta-cell close 
to insulitis area in pre-diabetic 12-week-old pancreas from NOD mice (Supplementary fig 
1.2D-F, 1.2 J-L, III). MANF expression was not detected in the insulitis area in the NOD 
islets (Supplementary fig 1.2D-F, 1.2 J-L, III). Other studies documented increased 
expression of Manf mRNA in the beta-cells of db/db mice at 12 weeks of age by RNA 
sequencing (Neelankal John et al., 2018). Consistently, in our studies, we reported that 
MANF expression is upregulated in beta-cell of db/db mice at 8 weeks of age by IHC 
(Supplementary Figure 1.2Q-S, 1.2 W-Y, III).  
Recent evidence indicates MANF protective effects against ER stress in beta-cells.  
Diminished Glis3 expression in beta-cells of immune-independent NOD mice led to decrease 
expression of MANF, where chronic ER stress and beta-cell apoptosis was caused by 
transgenic overexpression of hen lysozyme, suggesting that transcription factor Glis3 could 
regulate the expression of the Manf gene (Dooley et al., 2016). Reduced or lack of Glis3 
expression leads to neonatal diabetes in mouse and human (Senee et al., 2006; Watanabe et 
al., 2009). In contrast, Manf expression was upregulated in normal C57BL/6 mouse beta-
cells with ER stress caused by the hen lysozyme transgene expression (Dooley et al., 2016). 
However, upon HFD, Glis3 and Manf mRNA and protein expression were reduced, resulting 
in beta-cell apoptosis and diabetes (Dooley et al., 2016). Consequently, levels of MANF 
expression in beta-cells correlated with beta-cell survival in normal, diabetes-susceptible and 
stressed conditions. However, the exact relevance for MANF levels in diabetic beta-cells 
requires further exploration. 
5.  Genetic ablation of MANF in mice 
To understand the biological role of MANF, a detailed analysis of MANF conventional 
knockout (Manf-/-) mice and MANF conditional knockout mice was performed. 
5.1  Generation of Manf-/- mice  
(Original publication II and III) 
The MANF knockout mice (Manf−/−) were developed from a targeted embryonic stem (ES) 
cell  clone MANF_D06 (EPD0162_3_D06; C57Bl/6N-Manf tm1a(KOMP)Wtsi) that contained an 
efficient splice acceptor-site followed by a beta-galactosidase cassette inserted in the intron 
between exon 2 and exon 3 of the Manf gene, thus resulting in a constitutive null mutation 
through the splicing of exon 2 to the reporter cassette (Figure 1 A, II), confirmed by RT-PCR 
and Western blotting analysis (Supplementary Figure 1A, 1 B, II). The targeted Manf mutant 
allele in the Manf-/- mice contains Frt-sites that allowed removal of the strong splice-acceptor 
and beta-galactosidase cassette by the crossing of Manf+/- to globally expressing CagFlp-
recombinase transgenic mice (Supplementary Figure 2A, II, Supplementary Figure 2.1 A, 
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III). The resulting mice (Manffl/fl) are healthy and express Manf mRNA in tissues equally to 
Manf+/+ mice (Supplementary Figure 2B, II). In these mice, the Lox P sites (floxed) on both 
sides of exon 3 in the Manf locus enable conditional inactivation of the Manf gene by the 
crossing of mice to specific Cre-recombinase expressing mice. 
5.2  Absence of MANF causes diabetic phenotype and growth defect in conventional 
Manf-/- mice 
(Original publication Iand II) 
We found that MANF deficiency leads to a severe growth retardation and poor survival in 
both male and female mice in mixed Hsd:ICR(CD-1);C57BL/6 background (Figure 1 B, II). 
Manf-/- mice are significantly smaller already at E18.5 and continue to show weak growth 
(Figure 1 B, II). In addition, about 25% of the MANF-deficient mice die soon after birth 
whereas the rest of Manf-/- mice start to show signs of sickness between 8-11 weeks of age 
and most die before 12 weeks of age.  
The metabolic phenotype of 6-week-old MANF-deficient mice compared to WT mice 
was assessed for 60 h (2 days and 3 nights) in a Comprehensive Laboratory Animal 
Monitoring System (CLAMS). We observed that Manf-/-   mice consume more water 
(Supplementary Figure 1G, II), although food intake appears to be similar between the 
genotypes (Supplementary Figure 1H, II). Consumption of O2 and CO2 was significantly 
decreased in MANF-deficient mice compared to WT mice both during day and night 
(Supplementary Figure 1I, 1J, II). The respiratory exchange ratio was decreased in MANF-
deficient animals during the night (Supplementary Figure 1K, II), indicating that mainly fat 
is utilized as an energy substrate. In addition, we observed no changes in locomotor activity 
in open field arena between the genotypes (Supplementary Figure 1L, II). 
The metabolic phenotypes in Manf-/- indicated hyperglycemia and consequently blood 
glucose measurements showed that Manf-/- mice suffer from severe insulin-deficient diabetes. 
Signs of hyperglycemia and insulin deficiency were first noticed in random fed Manf-/- mice 
at P28 (Figure 5A, 5B) (Figure 1C, 1E, II), and the symptoms progressed with age. To 
confirm that the diabetic phenotype was not caused by the insertion of the beta-galactosidase 
cassette in the mouse genome, we first removed the beta-galactosidase cassette by crossing 
Manf+/- mice to CagFlp- expressing mice to generate Manffl/+ mice. Then we ubiquitously 
removed Manf from all cells by crossing of Manffl/fl mice with PgkCre transgenic mice. 
Consequently, we observed a similar diabetic phenotype with a severe growth retardation in 
PGKCre::Manffl/fl mice, confirming that the beta-galactosidase cassette did not cause the 
evident phenotypes in the Manf-/- mice. (Supplementary Figure 2C-E, II). On the contrary, 
recent studies revealed that global deletion of MANF in mice on C57BL/6 background led 
to perinatal lethality due to defects in breathing caused by reduced lung alveolar volume and 
abnormalities in lung development (Neves et al., 2016; Bell et al., 2019). In agreement, 
decreased survival of Manf-/- mice was detected in litters with increased rounds of 
backcrossing of Manf+/- mice in the ICR outbred strain to the inbred C57BL6 strain.  
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Figure 5. MANF-deficient mice develop diabetes. (A) Blood glucose levels measured in ad libitum-
fed Manf-/- mice, and their controls, n = 11-12 animals per group, both genders. (B) Serum insulin 
levels measured in Manf-/- mice and their controls from ad libitum-fed mice, n = 11-12 mice per group, 
both genders. (C) Blood glucose levels measured after intraperitoneal glucose (2 g/kg) injection in 8 
weeks old mice, n = 4 mice per group. 
Next, we performed physiological tests including glucose tolerance test (GTT) and insulin 
tolerance test (ITT). GTT measures the function of the beta-cells and insulin sensitivity, while 
ITT is used to addresses the insulin sensitivity of the whole body (Bowe et al., 2014). Our 
results revealed impaired glucose clearance and intact insulin sensitivity in the knockout 
animals at P56 (Figure 1F, II) (Figure 5C). Signs of impaired beta-cell function was detected 
already in 2-week-old Manf-/- mice as glucose challenge test showed decreased blood glucose 
clearance (Figure 1D, II) and barely detectable serum insulin levels in 8-week-old Manf-/- 
measured by ELISA (Figure 1G, II). To investigate, whether the function of beta cells from 
Manf-/- mice was affected, we analyzed insulin secretion on isolated islets after glucose 
stimulation in vitro (Figure 1H, 1I, II). The islets from diabetic MANF-deficient mice 
secreted significantly less insulin than Manf+/+ control islets at P35 under glucose stimulation 
for 1 hour. However, the ability of Manf-/- islets to secrete insulin in relation to total islet 
insulin content was not affected meaning that the capacity of Manf-/- beta-cells to secrete 
insulin was not reduced. In addition, the mRNA levels of glucokinase enzyme which 
phosphorylates glucose to glucose-6-phosphate important for ATP production and insulin 
release, was not reduced in islets isolated from Manf-/- mice (Figure 3, II). Therefore, we set 
out to study whether hyperglycemia was caused by loss of pancreatic beta-cells in Manf-/- 
mice.   
48 
Histological analysis of the Manf-/- pancreas revealed that the beta-cell mass in 
pancreases from embryonic E18.5 Manf-/- mice was similar to beta-cell mass in wt mice. 
However, at P1 the beta-cell mass had dropped by 50% compared to the control mice (Figure 
2A-F, 2G, II). Notably, the glucagon-positive alpha-cell mass was not reduced in the Manf-/- 
pancreases at any developmental stage quantified (Supplementary Figure 3D-I, 3G, II). 
However, the alpha-cells were no longer located in the border of islets but dispersed inside 
the islets, reflecting the progressive loss of beta-cells and disturbed islet architecture. 
The existing beta-cell mass results from a balance between the processes of beta-cell 
replication and beta-cell apoptosis. The beta-cells proliferate at the highest levels in mouse 
neonates, while this process declines with age (Teta et al., 2005).  
To reveal the mechanisms behind the reduction in beta-cell mass, we first set out to 
study, in pancreatic sections from mice, the rate of beta-cell proliferation (by quantification 
of the number of Ki67-positive beta-cells) and apoptosis (by TUNEL).The number of 
proliferating beta-cells was significantly reduced in the Manf-/- pancreas at P1 and P14 mice 
compared to Manf+/+ mice, whereas no reduction could be detected in embryonic E16.5 and 
E18.5 Manf-/- islets (Figure 2H, II), indicating that ablation MANF has no effect on beta-cell 
differentiation. However, even though MANF is highly expressed in pancreatic exocrine 
acinar cells, the proliferation rate of acinar cells was not affected in Manf-/- mice 
(Supplementary Figure 3B, II), suggesting that MANF is critically needed for proper beta-
cell proliferation. To verify if  beta-cell death contributes to reduced beta-cell mass, TUNEL 
staining followed by insulin staining on Manf-/- pancreases showed that the number of dying 
islet beta-cells was  significantly increased in Manf-/- pancreas at P14 and P56 (Figure 2J, 
Supplementary Figure 3C, II).  
To conclude, our results suggest that the progressive hyperglycemia in Manf-/- mice is 
triggered by postnatal loss of beta-cell mass due to decreased beta-cell proliferation and 
enhanced beta-cell apoptosis. 
We showed that global MANF-deficiency in mice resulted in a severe growth defect and 
a significant (16%) reduction in body length measured at 8 weeks of age (Supplementary 
Figure 1D-F, II). A recent study identified that cartilage-specific ablation of MANF in mice 
led only to a maximum of 5% reduction in skeletal bone and body length (Bell et al., 2019). 
Thus, the growth defect found in our Manf-/- mice in the ICR background indicated that 
ablation of MANF from other cell types rather than only cartilage resulted in the dwarfism 
in Manf-/- mice. 
In humans growth retardation or dwarfism is often caused by growth hormone (GH) 
deficiency (Raben, 1958). As GH is produced in the endocrine anterior pituitary and MANF 
was shown to be highly expressed by the adenohypophysis, we studied in more detail the 
Manf-/- mutant pituitary glands (Original publication I). Manf-/- pituitary glands revealed 
alteration of its cell composition compared to Manf+/+ as analyzed by hematoxylin-eosin 
staining. Notably, adenohypophysis of Manf-/- pituitary was affected by the reduced size and 
by decreased staining and ratio of granule-filled acidophilic cells (somatotropes and 
lactotropes) compared with Manf+/+ in 6 weeks old mice (Figure 6A-D, 6E, I).  
Consequently, the number of GH-positive and PRL-positive cells were reduced in the 
anterior lobe of the Manf-/- pituitary gland (Figure 6M-N, 6O-P, I). In addition the number of 
49 
proliferating pituitary cells assessed by Ki67 IHC were reduced (Figure 6S, Supplementary 
Figure 7C-D, I). There were no detectable changes in the apoptosis rates of the Manf-/- 
pituitary gland compared to Manf+/+ controls in 6 weeks of old mice (Supplementary Figure 
7E, I), suggesting that the reduced ratio of somatotropes and lactotropes was caused by the 
reduced proliferation rate.  
 Our further studies revealed that Gh mRNA and mouse Prl mRNA were reduced by 
50% and 79%, respectively, in mutant Manf-/- pituitaries compared to controls (Figure 6T, I). 
On the contrary levels of Pro-opiomelanocortin (Pomc) mRNA and Tshβ mRNA were 
significantly increased (Figure 6T, I). Luteinizing hormone β (Lhβ) and follicle-stimulating 
hormone (Fsh) mRNA levels were slightly decreased in Manf-/- pituitary glands at 6 weeks 
old male mice, while Fsh mRNA levels were significantly enhanced and Lhβ mRNA was not 
changed in Manf-/- female pituitary glands (Figure 6U, 6W, I). Pituitary-specific positive 
transcription factor 1 (Pit1) is required for the development of the anterior pituitary, 
particularly it plays role in the differentiation and maintenance of thyrotropes, somatotropes, 
and lactotropes (Cohen et al., 1996). We detected reduced levels of Pit1 mRNA expression 
in MANF-deficient pituitaries (Figure 6T, I), confirming the deficiency of both somatotropes 
and lactotropes in Manf-/- pituitary glands. 
Hence, our results propose that MANF is important for the maintenance of GH and PRL 
expressing cells in mice. Thus, MANF may have a pivotal role of MANF as a regulator of 
the maintenance of the acidophilic cells in the mouse pituitary gland. However, additional 
studies are required to elucidate the role of MANF in the regulation of growth. Interestingly, 
similarities with the phenotype of Manf−/− mice was also observed in Cdk4-null mice with 
specific endocrine phenotypes including infertility, dwarfism and diabetes (Rane et al., 1999; 
Tsutsui et al., 1999). As with MANF, Cdk4 was shown not to be vital during mouse 
development but required for the postnatal proliferation of pancreatic beta-cells, 
somatotrophs and lactotrophs (Rane et al., 1999; Tsutsui et al., 1999; Jirawatnotai et al., 
2004). Hence, defects in the proliferation of MANF-deficient beta-cells, somatotropes and 
lactotropes could be associated with alteration in CDK4. 
The role of MANF in humans is not yet defined. In vitro, endogenous MANF seems to 
be replaceable for the survival of primary human beta-cells (Hakonen et al., 2018). However, 
when treated with inflammatory cytokines, beta-cells with reduced MANF-expression were 
significantly more vulnerable to beta-cell death compared to beta-cells with normal MANF 
levels (Cunha et al., 2017). Interestingly, a clinical exome sequencing study of Middle 
Eastern patients with neurocognitive phenotypes revealed a young 22-year-old patient with 
a homozygous missense mutation in the splice donor site in exon 1 of the human MANF gene 
suggesting total lack of MANF or hypomorphic MANF expression in this patient (Yavarna 
et al., 2015).  She was reported to suffer from obesity, T2D, short stature, mild intellectual 
disability, microcephaly, hypothyroidism, and primary hypogonadism, myopia, and 
autoimmune alopecia (Yavarna et al., 2015), which partly recapitulating phenotypes of the 
MANF knockout mice. However, to date patients with similar mutations have not yet been 
reported. Increased levels of MANF in blood serum was found at the manifestation of T1D 
in children before puberty, although no changes were detected in older children and teenagers 
with recent-onset T1D or in adults with prolonged T1D (Galli et al., 2016). Moreover, 
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circulating MANF levels were significantly enhanced in newly diagnosed insulin resistant 
pre-diabetic and type 2 diabetic patients (Wu et al., 2017). However, it remains to be studied 
if elevated MANF in serum blood of T1D and T2D patients are related to impaired beta-cell 
function. Our recent study revealed that MANF secretion was stimulated by cytokines from 
a human beta-cell line EndoC-H1 (Hakonen et al., 2018), thus suggesting stressed beta-cells 
as a source of increased MANF secretion into the bloodstream in newly diagnosed T1D and 
T2D. 
5.3.  Analysis of MANF functions in conditional knockout animals  
(Original publication III) 
We specifically deleted MANF from the embryonic pancreas by crossing Pdx-1CreTUV 
mouse line (Jackson Laboratories, Stock 014647) (Hingorani et al., 2003) to Manffl/fl mice. 
To evaluate the Pdx-1Cre recombinase activity, we crossed Pdx-1Cre mice with Rosa26-
tdTomatofl/Stop/fl reporter mice (Jackson Laboratories, Stock 007914). To address the roles for 
MANF in postnatal/adult beta-cells in vivo, we ablated MANF from the beta-cells in adult 
mice by using tamoxifen (Tmx)-inducible MIP1-CreERT mice (Tamarina et al., 2014) 
crossed to Manffl/fl mice. 8-weeks-old MIP1-CreERT::Manffl/fl animals received 33 mg/kg of 
Tmx for 5 consecutive days and control mice were injected with corn oil. Four weeks post 
injections, mice were assessed for different analysis. To ensure that diabetic phenotype of the 
MANF knockout mice was not caused by MANF deletion from the brain, we crossed rat 
promoter NestinCre transgenic mice (a gift from Edgar Kramer (B6.Cg-Tg(Nes-cre)1Kln/J) 
to Manffl/fl mice. 
5.3.1 Pancreas specific ablation of MANF in mice 
(Original publication II and III) 
The roles of MANF specifically in the mouse pancreases was addressed by crossing Manffl/fl 
mice with transgenic PDX1-Cre mice.  
The specificity of Pdx1Cre recombinase activity was examined in the pancreas, and 
other tissues of Pdx1-Cre+/- mice crossed to tdTomato reporter mice (Jackson Laboratories, 
Stock 007914). We observed Cre-mediated tdTomato red fluorescence signal in several 
mouse tissues, including pancreas, duodenum, and liver at different embryonic and postnatal 
stages (Supplementary Figure 2.2K-DD, III), although Pdx1Cre-mediated recombination 
was reported in the developing pancreas, antral stomach and duodenum of the newborn 
animals and pancreatic beta-cells postnatally (https://www.jax.org/strain/014647). No 
ectopic Cre activity was found in MANF expressing brain cells in the cortex, hippocampus, 
and hypothalamus in MANF conditional animals compared to controls (Supplementary 
Figure 2.2A-J, III), suggesting that MANF expression in the brain do not cause diabetes in 
Pdx-1Cre+/-::Manffl/fl mice. 
In accordance with phenotype of Manf-/- mice, conditional Pdx-1Cre+/-::Manffl/fl mice 
develop insulin-deficient diabetes (Original publications II, III). Interestingly, we observed 
a slightly delayed onset of diabetes in Pdx-1Cre+/-::Manffl/fl mice compared to Manf-/- mice. 
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Pdx-1Cre+/-::Manffl/fl mice start to show a slight decrease in weight starting at P56 
(Supplementary Figure 2.1B, III), when animals become hyperglycemic (Supplementary 
Figure 2.1C, III). This implies that the weight reduction is caused by the diabetes and that 
ablation of MANF from other tissues rather than beta-cells results in the growth retardation 
seen in global Manf-/- mice. 
No changes in the blood glucose levels were observed in P1 and P14 of ad- libitum fed 
Pdx-1Cre+/-::Manffl/fl mice compared to control Manffl/fl mice (Supplementary Figure 2.1B, 
III). Acute hyperglycemia and a significant decrease in serum insulin levels were observed 
in P56 Pdx-1Cre+/-::Manffl/fl mice (Supplementary Figure 2.1D, III). To characterize a 
metabolic phenotype in conditional animals, we performed intraperitoneal GTT, which 
revealed the inability of P56 Pdx-1Cre+/-::Manffl/fl mice to clear glucose from the blood 
stream (Supplementary Figure 2.1E, III). However, we noted that glucose-stimulated insulin 
levels were not significantly downregulated 30 minutes after glucose injection in conditional 
knockout animals at P56 (Supplementary Figure 2.1F, III), indicating that the function of the 
beta-cells in Pdx-1Cre+/-::Manffl/fl mice is not completely diminished compared to their 
controls. As with global Manf-/- mice, ITT revealed intact insulin sensitivity in the Pdx-
1Cre+/-::Manffl/fl mice at P42 (Supplementary Figure 2.1G, III), indicating that these mice 
respond to insulin by lowering of blood glucose levels.  
Consistent with our previous results (II), we detected marked loss of islet structure and 
a deficit of insulin staining in the pancreases of P56 Pdx-1Cre+/-::Manffl/fl mice 
(Supplementary Figure 2.1I-N, III). In opposite to Manf−/− mice, no changes were detected 
in the beta-cell mass at P1 of Pdx-1Cre+/-::Manffl/fl mice, whereas a significant decrease 
appeared in P14 mice (Supplementary Figure 2.1U, III). As the beta-cell mass was not altered 
in MANF-deficient pancreases at E18.5 and in P1 conditional Pdx-1Cre/+::Manffl/fl mice, we 
suggest that MANF is not required for the differentiation of beta-cells via the processes of 
neogenesis or proliferation before birth. Further analysis revealed a reduced number of Ki67 
positive beta-cell in P14 conditional mice, but not in P1 and P56 animals (Supplementary 
Figure 2.1W, III). Increased levels of apoptosis were detected in Pdx-1Cre+/-::Manffl/fl mice 
at P14 and P56 assessed by TUNEL staining (Supplementary Figure 2.1X, III). 
Generally, our results demonstrate that embryonic ablation of MANF specifically from 
the pancreatic beta-cells leads to insulin-deficient diabetes caused by the postnatal reduction 
of the beta-cell mass due to the increased beta-cells apoptosis and decreased beta-cell 
proliferation.  Interestingly, abnormalities in beta-cell proliferation and beta-cell apoptosis in 
conditional animals were detected later than in Manf -/- mice, resulting in the delayed 
phenotype of Pdx-1Cre+/-::Manffl/fl. 
The efficiency of conditional beta-cell targeting influences the experimental outcome 
(Magnuson and Osipovich, 2013).  Consistent with other studies (Gannon et al., 2000; 
Herrera, 2000; Steneberg et al., 2005), we observed that Pdx-1Cre+/-::Manffl/fl mice exhibit a 
mosaic recombination pattern in both exocrine acinar cells and endocrine islets in adults 
(Figure 2F, Supplementary Figure 2.3A-I, III). However, MANF positive cells were found 
within the Langerhans islet and pancreatic blood vessels of P1 Pdx-1Cre+/-::Manffl/fl due to 
incomplete recombination (Supplementary Figure 2.3K-O, III). Furthermore, mosaic 
immunoreactivity of MANF was observed in pancreases of Pdx-1Cre+/-::Manffl/fl  at P14 with 
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the degree of variation, and even wider MANF expression was observed in adult conditional 
exocrine acinar and endocrine beta-cells (Figure 2F, Supplementary Figure 2.3A-I, III). 
Hence, diabetes in Pdx-1Cre+/-::Manffl/fl mice occur later than in Manf-/- mice possibly due to 
non-recombined islet cells expressing MANF. 
Remarkably, certain mice did not show any MANF expression even in the adult age 
(Figure 2C, III). Accordingly, we observed a significant reduction of Manf mRNA levels in 
the islets derived from Pdx-1Cre+/-::Manffl/fl mice compared to Manffl/fl at P1, P14 and P56 
(Supplementary Figure 2.3J, III).  Importantly, we detected an altered structure of endocrine 
islets and decreased expression of insulin-positive beta-cells in the pancreases of conditional 
mice (Figure 2A, 2J-O, III). When MANF expression was present in the beta-cells of the 
Langerhans islets, the morphology of the islet remained intact with the peripheral distribution 
of alpha-cells (Figure 2D, 2E III). We also noticed a loss of membrane expression of the 
glucose transporter 2 (GLUT2) in the beta-cells lacking MANF (Figure 3H-N, III). 
Our results demonstrated that the number of MANF-positive beta-cells correlated with 
the beta-cell mass (Figure 2P, III), and consequently with blood glucose levels (Figure 2Q, 
III) in the Pdx-1Cre+/-::Manffl/fl mice. Also, a significant negative correlation was observed 
with the level of beta-cell apoptosis in individual mice (Figure 2R, III), further revealing that 
MANF is essential for the recovery of the beta-cell mass and maintaining the beta-cell 
phenotype.  
5.3.2 Deletion of MANF specifically from beta-cells of adult mice  
(Original publication III) 
The analysis of MIP1-CreERT::Manffl/fl mice injected with Tmx revealed no changes in the 
weight of these mice (Figure 5A, III). However, the blood glucose levels of the random fed 
ad-libitum mice were increased (Figure 5B, III), and insulin levels were significantly reduced 
(Figure 5C, Supplementary Figure 5.1A, III), as compared to oil injected mice. 
Physiologically, lack of MANF in adult beta-cells of Tmx injected MIP1-CreERT::Manffl/fl 
resulted in impaired glucose tolerance in vivo shown by GTT (Figure 5D, Supplementary 
Figure 5.1B, III). ITT results indicated that insulin sensitivity was not abolished in Tmx 
injected MIP1-CreERT::Manffl/fl animals (Supplementary Figure 5.1C, III), meaning that 
diabetic phenotype displays a deficiency of insulin production and/or secretion. Additionally, 
serum insulin levels after GTT were significantly downregulated in Tmx MIP1-
CreERT::Manffl/fl animals (Supplementary Figure 5.1D, III). 
Moreover, deletion of MANF in the adult beta-cells led to reduced amounts of islets 
insulin content and as a result – decreased levels of glucose-stimulated insulin in vitro (Figure 
5E-F, III), suggesting that the secretion pathway is functionally intact. However, in response 
to high glucose together with the 3-isobutyl-1-methylxanthine (IBMX), which is known to 
raise islet cAMP levels, the MANF-deficient islets secreted more insulin compared to islets 
from oil-injected mice.  cAMP-stimulated insulin release is controlled by intracellular 
calcium (Siegel et al., 1980). As ER stress is known to release calcium from ER stores and 
increase cytosolic calcium, the higher insulin secretion from MIP1-CreERT::Manffl/fl  islets 
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might be due to ER stress leading to higher cytosolic Ca2+ which might potentiate the insulin 
secretion from the islets treated with IBMX.  
Even though secreted insulin levels from islets of MIP1-CreERT::Manffl/fl  Tmx mice 
were reduced, the ability to secrete insulin in relation to total islet insulin content remained 
the same under glucose stimulation except for the condition with IBMX (Figure 5G, III).  
Histological analysis of pancreases showed clusters of MANF-expressing cells (about 
15% of the beta-cells) after the Tmx injection in MIP1-CreERT::Manffl/fl mice (Figure 5H-
M, III), which could be due to incomplete recombination and expansion of MANF-
expressing beta-cells At the same time, we observed a nearly 50% reduction in Manf mRNA 
expression in the islets  of oil injected MIP1-CreERT::Manffl/fl  mice, compared to Manffl/fl 
islets , which could be due to leakiness of the system resulting in Cre-translocation into the 
nucleus even in the absence of Tmx. In accordance with reduced MANF IHC signal in the 
islets of MIP1-CreERT::Manffl/fl mice, Manf mRNA levels were significantly reduced in 
isolated islets from Tmx injected MIP1-CreERT::Manffl/fl mice ( Supplementary Figure 5.1E, 
III). 
Importantly, analysis of pancreatic tissue showed that the deficiency of MANF in the 
beta-cells of MIP1-CreERT::Manffl/fl mice injected with Tmx caused beta-cell loss and 
decreased insulin expression (Figure 5O, III), a significant decrease of the beta-cell mass 
(Figure 5R, Supplementary Figure 5.1X, III), and a minor non-significant changes in the 
alpha-cell mass (Supplementary Figure 5.1Z, III) compared to oil injected control group.  
Additionally, we detected a significant reduction in beta-cell proliferation (Figure 5S, III) 
and a significant increase in apoptosis (Figure 5T, III) of beta-cells in Tmx MIP1-
CreERT::Manffl/fl mice. Moreover, we detected the reduced expression of PDX1 and GLUT2 
in the adult beta-cells lacking MANF.  
Thus, removal of MANF from the beta-cells postnatally led to the development of 
diabetes, as a result of reduced beta-cell proliferation and enhanced beta-cell apoptosis. This 
observation strongly suggests that MANF expression is needed for the beta-cell maintenance 
in adult mice. 
5.3.3 Ablation of MANF in CNS specific mice does not cause a diabetic phenotype  
(Original publication II, unpublished results) 
The Nestin-Cre mouse model is commonly used to conditionally ablate or express particular 
genes in the neuronal cells of the CNS and PNS (Tronche et al., 1999). Although nestin is a 
marker for neuronal progenitor cells, its expression has been documented in several other 
tissues outside the CNS and PNS, including multipotent stem cells of the pancreatic 
primordium and kidney cells (Delacour et al., 2004; Dubois et al., 2006; Kedees et al., 2007). 
However, Cre-mediated recombination was observed in pancreatic exocrine cell lineage and 
not in the islet endocrine progenitor cells studied by cell lineage analysis (Delacour et al., 
2004). 
Recent study revealed that the level of MANF expression in the mouse hypothalamus is 
regulating food intake and thus insulin sensitivity (Yang et al., 2017) (chapter 1.4.4). 
However, the analysis of the random fed ad-libitum 1.25-1.5-year-old NestinCre+/-::Manffl/fl 
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mice revealed no signs of diabetes as their blood glucose and serum insulin levels were not 
changed compared to control Manffl/fl mice (Supplementary Figure 1J, 1K, II). Analysis of 
MANF expression in the pancreases of NestinCre+/-::Manffl/fl revealed patchy mosaic 
expression in exocrine tissue, but normal distribution in the islets of Langerhans (Figure 6). 
Consequently, histological analysis of the NestinCre+/-::Manffl/fl pancreases indicated intact 
islet structure with the peripheral distribution of alpha-cells (Figure 7). 
 
Figure 6. MANF expression is not affected in the islets of NestinCre+/-::Manffl/fl mice (B,C) compared 
to the Manffl/fl (A), Manf+/+ (D), and Manf−/− (E) mice. Scale bar, 50 µm. 
 
Figure 7. Structure of islets in NestinCre+/-::Manffl/fl mice is not affected. (A-F) MANF (A, D), insulin 
(B, E) and glucagon (C, F) immunohistochemistry on pancreas sections from NestinCre+/-::Manffl/fl 
and Manffl/fl mice. Scale bar, 20 µm.  
5.4  Activation of ER stress and UPR in the MANF deficient islets and pituitary glands  
(Original publication II, III) 
The mechanisms behind the reduced beta-cell mass and reduced number of acidophilic cells 
in the anterior pituitaries in MANF-deficient mice remained to be studied. As MANF has 
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been implicated in the regulation of the UPR and UPR is known to affect cell proliferation 
and lead, if chronic, to cell death, we set out to test level of UPR activation in the beta-cells 
and pituitaries of MANF-deficient mice. Pancreatic beta-cells are especially sensitive to ER 
stress due to their substantial need for insulin synthesis and secretion in order to regulate 
glucose homeostasis (Eizirik and Cnop, 2010). We observed chronic activation of all UPR 
branches and unresolved ER stress in the islets lacking MANF. First, we identified the 
upregulation of Grp78 and spXbp1 mRNA in the IRE1 pathway in the E18.5 pancreases 
from Manf -/- mice. In isolated pancreatic islets of Manf -/- mice at P1 and P14 (Figure 4A-C, 
II) we found increased activation of genes in the PERK and ATF6 pathway. Moreover, we 
observed increased levels of phospho-eIF2α in islets derived from MANF knockout mice at 
P14, P28, and P56 (Figures 4D, 4E, II), indicating constitutive activation of PERK pathway 
in the Manf−/− islets postnatally. The absence of MANF in the pancreas of Pdx-1Cre+/-
::Manffl/fl mice leds to upregulation of UPR markers and chronic ER stress in pancreatic islets 
from P1  and onwards (Figure 3D, 3E, III). Importantly, the ablation of MANF in the adult 
beta-cells also resulted in the initiation of ER stress by a significant increase of Grp78, Chop, 
Atf4, Atf6α, and Atf6β mRNAs (Figure 6B, III). However, mRNA levels of spXbp1 and 
totalXbp1 were unchanged (Figure 6B, III), at the time of analysis 4 weeks after Tmx 
injections. Thus increased expression of spXbp1 could have already preceded the 
upregulation of PERK and ATF6 pathways as in global Manf-/- and Pdx-1Cre+/-::Manffl/fl 
mice.  
However, beta-cell mass, number of proliferating beta-cells and mRNA of different 
beta-cell markers were not yet reduced neither at E18.5 pancreases of Manf -/- mice nor in P1 
islets of Pdx-1Cre+/-::Manffl/fl mice (Figure 3A, II, Figure 3A, III). The downregulation of 
the beta-cell mass and consequent decrease of Glut2, Ins1/2, Pdx1 and MafA beta-cell 
markers were observed in the islets of Manf -/- mice starting from P1 and Pdx-1Cre+/-::Manffl/fl 
mice starting from P14 (Figure 3B, 3C, 3D, II, Figure 3B, 3C, III). Therefore, ER stress 
caused by MANF-deficiency seemed to precede the impaired beta-cell function. 
Since the phenotype of Manf-/- mice is associated with the activation of ER stress and 
chronic UPR activation in pancreatic beta-cells, we investigated whether ablation of MANF 
from the pituitary gland leads to ER stress and activation of the UPR. Indeed, Grp78, Chop, 
spXbp1, Atf4, Atf6α, Atf6β mRNAs were significantly upregulated (Figure 6W, I), indicating 
severe chronic activation of all three central UPR pathways PERK, IRE1 and ATF6 in the 
pituitary glands of 6 weeks old Manf-/- mice lacking MANF. Consequently, as with the beta-
cells, activation of those pathways seem to lead to reduced cell proliferation in the anterior 
pituitary. No increased cell death was observed in the anterior pituitaries of Manf-/- mice at 6 
weeks, although apoptotic Chop mRNA levels were increased. 
ER stress and activation of the UPR is associated with the pathogenesis of T1D and T2D 
(chapter 3.5.1 and 3.5.2) as well as diabetic phenotypes occur due to genetic alteration in 
several factors essential for the ER homeostasis (chapter 3.5.3). Similarly to MANF knockout 
mice, inactivation of several UPR genes in mice lead to the development of diabetes due to 
the loss of the beta-cells (chapter 3.5.3). Interestingly, similarly to Manf-/- mice Perk mutation 
in human and mice leads to skeletal dysplasia, growth retardation and diabetes (Zhang et al., 
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2002). ATF4 is also involved in normal osteoblast differentiation and growth (Yang et al., 
2004).  
Taken together, MANF is an essential factor that regulates cell homeostasis and survival 
similarly to other UPR proteins. 
5.5  Activation of signaling pathways in the islets of Manf-/- mice  
(Original publication III) 
MANF remains an orphan ligand, as its signal transduction receptor has remained elusive. 
So far, studies showed that MANF interacts with GRP78 and consequently regulates protein 
folding in the ER (Glembotski et al., 2012; Yan et al., 2019). The studies by Henderson et al. 
showed that MANF weakly binds to KDEL receptors (Henderson et al., 2013), although the 
direct binding was not confirmed. Recent studies identified that MANF binds to sulfatides at 
cell membranes of C. elegans and mammalian cells and this interaction enhances subsequent 
cellular uptake of MANF resulting in cytoprotection from hypoxia-induced cell death (Bai et 
al., 2018).  
The exact signaling pathways activated by MANF remain undefinable. It was 
demonstrated that the PKC signaling cascade is activated after stimulation with 1.5 mg/ml of 
MANF in PC12 cells in vitro (Yang et al., 2014a). It was shown that MANF regulates NF-
κB and p38 (MAPKs) pathways (Chen et al., 2015b; Zhu et al., 2016). Specific DmMANF 
knockdown in glia cells of Drosophila resulted in the appearance of a microglia-like cell 
type, which is characterized by expression of the NF-kB factor Relish (Stratoulias and Heino, 
2015). Moreover, MANF was shown to protect neurons via the induction the PI3K/AKT 
signaling cascade (Zhang et al., 2017b; Gao et al., 2018; Xu et al., 2018). In contrast, reduced 
AKT phosphorylation was observed after increased expression of MANF in the 
hypothalamus of MANF-transgenic mice, leading to impaired insulin signaling, insulin 
resistance and hyperphagia (Yang et al., 2017). 
We are the first to show that exogenous MANF can induce beta-cell proliferation and 
protect against ER stress-induced mouse and human beta cell death in vitro (chapter 6.1). 
However, the mechanisms involved in these processes are still unclear. In order to study the 
effects of exogenous MANF in beta-cells in vitro, we isolated islets derived from Manf+/+ 
and Manf-/- mice and cultured the beta-cells in the presence or absence of MANF.  Islet lysates 
were subjected to Western blotting using different sets of cell signaling antibodies or mRNA 
from islets was subjected to RT-qPCR. Upon addition of MANF to WT and KO islets, we 
observed an increase in AKT (Ser473) phosphorylation, suggesting that MANF exerts its 
proliferative effects on the beta-cells via PI3K/AKT cascade (Figure 7A, 7B, III), which is 
one of the important pathway involved in mitogenic responses in rodent and human beta-
cells  and can be initiated by many growth factors like insulin, IGF-1, HGF, GLP-1 (Elghazi 
and Bernal-Mizrachi, 2009; Szabat et al., 2016). ERK/MAPK signaling pathway is also 
known to promote beta-cell replication and can be initiated by PDGF, EGF receptor and 
insulin receptor (Cras-Meneur et al., 2001; Chen et al., 2011; Siddle, 2011). However, we 
did not observe activation of the ERK pathway in the mouse beta-cells upon addition of 
MANF (Figure 7E, 7F, III). 
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Recent study indicated that PDGF-mediated MANF expression stimulated anti-
inflammatory effects in the injured retina, thus leading to retinal tissue repair in mice and 
fruit flies (Neves et al., 2016). The analysis of the signaling cascades in MANF deficient 
islets revealed activation of pro-inflammatory pathways including p38MAPK, NF-κB and 
JNK (Figure 7G, 7H, 7K, 7L, 7M, 7N, III), initiation of which results in deleterious effects 
of the beta-cells (chapter 3.5.1). Studies with human beta-cells revealed that MANF 
protective properties are associated with the repression of the NF-κB signaling pathway 
(Hakonen et al., 2018). Moreover, treatment of primary human islets with cytokines and 
MANF led to downregulation of apoptotic BCL10 (Hakonen et al., 2018), which binds to 
TRAF2 thereby leading to apoptosis and activation of NF-B (Yoneda et al., 2000). 
Consequently, we detected that Bcl10mRNA levels were significantly enhanced in Pdx-
1Cre+/-::Manffl/fl islets at P1 (Figure 7I,7J, Supplementary Figure 6B, III). Moreover, we 
detected enhanced expression of iNOS in the Manf-/- islets (Figure 7O, 7P, III), thus possibly 
leading to NO production. Additionally, upregulation of c-Jun phosphorylation in KO islets 
was detected (Figure 7K, 7L, III). Hence, the protective effects of MANF can be mediated 
by immune modulation. 
 Furthermore, increased levels of Trib3 mRNA was detected (Figure 7C, 7D, III), which 
is a negative regulator of AKT phosphorylation (Du et al., 2003). It is known that ATF4 in 
the PERK-pEIF2 pathway regulates the expression of Trib3 (Cunard, 2013), thus the 
reduced phospho-AKT in MANF-deficient islets could be caused by increased ATF4 
expression that upregulates the expression of Trib3 leading to increased inhibition of AKT 
phosphorylation (Figure 7A, 7B, III). Hence, we could speculate that the reduced AKT-
phosphorylation in Manf-/- beta-cells leads to decreased beta-cell proliferation due to chronic 
activation of the UPR and specifically the PERK pathway. In addition, increased 
inflammatory signaling leading to beta-cell death of Manf-/- islets might be caused by 
increased IRE1 and PERK activation. Consequently, MANF might dampen the ER stress 
in beta-cells thus favour beta-cell proliferation and protection. 
The summary of the signaling pathways activated in response to MANF deficiency in 
the beta-cells provided in the Figure 8. 
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Figure 8. Illustration of signaling pathways activated in response to MANF deletion from mouse 
pancreatic islets based on results provided in chapters 5.4 and 5.5. Chronic activation of all three 
central UPR pathways PERK, IRE1 and ATF6 were observed in pancreatic islets deficient to MANF 
that was accompanied by the activation of pro-inflammatory signaling cascades including p38MAPK, 
NF-κB and JNK. Levels of pro-apoptotic Bcl10 were significantly enhanced as well as iNOS 
expression. Increased expression of Trib3 resulted in inhibition of AKT phosphorylation in MANF-
deficient islets. ATF6, activating transcription factor 6; PERK, protein kinase R-like endoplasmic 
reticulum kinase; IRE1, inositol-requiring enzyme 1; NF-κB, nuclear factor κ-light-chain-enhancer 
of activated B cells; JNK, c-Jun N-terminal kinases, iNOS, inducible nitric oxide synthase: NO, nitric 
oxide; BCL10, B-cell lymphoma/leukemia 10; TRIB3, tribbles homolog 3.  Modified from 
(Danilova and Lindahl, 2018). 
6.  Therapeutic effects of MANF 
As therapeutic strategies for the development of new molecular regulators of endogenous 
beta-cell regeneration is under intensive investigation  for the treatment of diabetes 
(Vasavada et al., 2006; Tarabra et al., 2012), we set out to study the regenerative effect of 
MANF in vitro on primary mouse beta-cells as well as in vivo in a mouse model of T1D.  
6.1  Exogenous effect of MANF on primary mouse beta cells 
(Original publication II, III and (Cunha et al., 2017)) 
Based on the result that Manf-/- mice have reduced beta-cell proliferation compared to WT 
mice, we speculated if MANF protein could affect the replication of the mouse beta-cell in 
culture. Our results demonstrated that MANF can stimulate beta-cell proliferation in isolated 
islets in vitro prepared from young adult (12 weeks of age) (Figure 5A, II). Notably, MANF 
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in combination with PL showed an additive effect in the proliferation efficiency on young 
adult mouse beta-cells implying different mitogenic intracellular signaling cascades for 
MANF from PL, which is known to stimulate beta-cell replication trough Janus kinase-signal 
transducer JAK2/STAT5 pathway (Amaral et al., 2003).  
Expansion of the beta-cell mass occurs under the process of beta-cell proliferation 
postnatally (Dor et al., 2004). However, replication of the beta-cells deteriorates in rodents 
and humans with advanced age as well as the ability of aged beta-cells to respond to the 
mitogenic factors (Teta et al., 2005; Kushner, 2013). Importantly, we showed that MANF 
enhances the proliferation of the beta-cells of even aged mice (15-month-old mice) (Figure 
4A, III). With collaborative efforts, we demonstrated that MANF in combination with TGFβ 
promoted enhanced primary human beta-cell proliferation (Hakonen et al., 2018), which 
rarely replicate. Taken together, the MANF is capable to stimulate replication of the beta-
cells from even aged mice and humans imply that MANF is a mitogenic factor for pancreatic 
beta-cells. 
Furthermore, our studies evaluated the ability of MANF to inhibit beta-cell apoptosis 
under several ER stress conditions. We showed that thapsigargin upregulated Manf mRNA 
expression in mouse beta-cells in vitro and that MANF was able to decrease thapsigargin-
induced apoptosis (Cunha et al., 2017) (Figure 9). In addition, treatment of mouse beta-cells 
in media supplemented with high glucose significantly upregulated Manf mRNA in vitro 
(Figure 4K, III) (Figure 9), suggesting that hyperglycemia in mice and human leads to 
upregulation of MANF expression in the beta-cells in vivo. MANF able to decrease 
hyperglycemia-induced ER stress in mouse beta-cells in vitro (Figure 4L-N, III). 
 
Figure 9. Quantitative RT-PCR analysis of Manf gene expression in primary mouse pancreatic 
islets treated with 1 µM thapsigargin for 6 hours in RPMI medium supplemented with 0.5% BSA. n 
= 2 wells per group. 
 Finally, we showed that the addition of MANF to the MANF-deficient islets in the culture 
medium led to increased beta-cell proliferation (Supplementary Figure 4A, III) and reduced 
levels of ER stress markers compared to untreated islets (Supplementary Figure 4B, 4C, III). 
Our collaborative studies demonstrated that MANF is secreted from in human beta-cells 
upon stimulation with pro-inflammatory cytokines in vitro (Hakonen et al., 2018). 
Importantly, MANF partially protected both mouse and human beta-cells from cytokine and 
ER stress-induced cell death in vitro (Cunha et al., 2017; Hakonen et al., 2018). Pathogenesis 
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of T1D is associated with the production of pro-inflammatory cytokines that trigger 
activation of ER stress and UPR in the beta-cells (chapter 3.1 and 3.5.1), therefore MANF is 
especially essential factor T1D therapy. 
To conclude, our results show that MANF is an essential factor with mitogenic and 
defensive properties for both mouse and human beta-cells. Hence, the effects of MANF in 
vitro make it a promising target for the treatment of diabetes.  
6.2  Adeno-associated virus (AAV) vector-mediated overexpression of MANF in the 
pancreases by intraductal delivery partially protects beta-cells in STZ mouse 
model 
(Original publication II) 
To study the therapeutic potential of MANF on mouse beta-cells in vivo, we proceeded with 
intraductal delivery of adeno-associated virus vector serotype 6 (AAV6) -MANF and AAV6-
RFP as a control into the pancreases of mice, followed after 3 weeks by multiple low-dose 
streptozotocin (MLDS) injections in order to induce diabetes in mice (Figure 5B, II). STZ is 
a toxic glucose analog that selectively enters rodent beta-cells via GLUT2 and subsequently 
kills beta-cells (Schnedl et al., 1994). MLDS is generally used in experiments attempting to 
reproduce mild insulin-dependent diabetes mellitus in rodents. For accurate study design, we 
considered performing STZ injections in 3 weeks after the intraductal delivery of AAV6-
MANF and AAV6-RFP in order to let MANF and RFP overexpress (Figure 5B, II).  
Mice were monitored for blood glucose levels and sacrificed 3 weeks after the first STZ 
injection when control mice were highly hyperglycemic. The blood glucose and serum 
insulin levels were similar between the control and treatment groups indicating that MANF 
did not have significant therapeutic effect in this experiment (Supplementary Figure 5M, 5N, 
II). Histological analysis of the pancreases of these mice revealed that only about 4% of beta-
cells and exocrine tissue were transduced with the virus, indicating a partial delivery and 
over-expression of MANF and RFP (Supplementary Figure 5A-K, II), which could explain 
the negative therapeutic effect. Nevertheless, we observed that insulin-positive islets were 
significantly more abundant and larger in the AAV6-MANF-STZ-treated group compared to 
the AAV6-RFP-STZ-treated mice (Figure 5C, Supplementary Figure 5D, 5H, 5L, II). 
Importantly, overexpression of MANF in the pancreas seemed to increase beta-cell 
proliferation but not exocrine acinar cell proliferation measured by Ki67 IHC and protect 
from beta-cell death assessed by TUNEL in our MLDS mouse model of diabetes (Figure 5D, 
5F, II). 
Hence, overexpression of MANF in beta-cell demonstrated regenerative and protective 
effects on beta-cells in MLDS mouse model of T1D. Taking into account the limitations of 
this study such as low-transduction efficiency of virus-delivered MANF, more research is 
required to address the therapeutic potential of MANF in diabetes. We have thus produced 
beta-cell-specific MANF-overexpressing transgenic mice which will be used to further 
validate the role of MANF-overexpression in mouse diabetes models.  
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7.  Morphological analysis of pancreatic tissues with deep convolutional 
neural network 
(Manuscript IV) 
Deep convolutional neural network (dCNN) based algorithms are a very effective method in 
the objects and patterns recognition, which is successfully employed in medical and 
biological research. dCNN is applicable to use for cell areas quantifications, as well as, 
individual cells with the advantages in reduced human errors, decreased variability, and faster 
analysis, which all increase the analysis capacity. We implemented the analysis of the mouse 
whole pancreatic sections immunolabeled with either insulin or glucagon antibody to count 
beta- and alpha-cell areas following by quantification of the beta-, alpha- and islet-cell mass. 
Importantly, by using dCNN we obtained islet-cell areas results from the slides stained with 
either insulin or glucagon antibodies. Next, we compared the results of dCNN method to our 
previously published results using pancreatic sections from diabetic conventional and 
conditional MANF-deficient mice and their controls. Our data demonstrated that dCNN for 
the morphological analysis of the mouse pancreatic tissue is a highly accurate method. We 
obtained a significant correlation between the results of the traditional method and the dCNN 
algorithms. The new approach will noticeably increase the analysis performance and generate 
high-quality data from pancreatic sections examination (in average 1 minute 4 seconds for 
the analysis of 1 pancreatic section, which is about 6x times faster than the analysis done by 
manual methods). 
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SUMMARY AND CONCLUSIONS  
The main aim of this thesis was to investigate the biological functions of MANF in vivo. The 
following findings were presented in this thesis: 
I. Extensive expression analysis of MANF protein and mRNA in different mouse tissues 
revealed that MANF is highly expressed in the mouse tissues with metabolic function, 
especially in glandular cells with the high secretory function. 
II. We showed that the global lack of MANF leads to insulin-dependent diabetes and 
growth retardation in mice. The diabetic phenotype of Manf-/- mice was caused by 
progressive postnatal loss of beta-cell mass due to the postnatal decrease in the beta-
cell proliferation and increased apoptosis. The growth defect in MANF-deficient mice 
could partly be caused by the reduced size of the anterior pituitary gland and decreased 
number of growth hormone producing cells. 
III. Embryonic ablation of MANF specifically from the pancreas in Pdx-1Cre+/-::Manffl/fl 
conditional knockout mice resulted in the loss of beta-cells and diabetes similarly to 
Manf-/-. However, incomplete recombination and mosaic MANF expression in 
postnatal pancreases of Pdx-1Cre+/-::Manffl/fl mice revealed a significant correlation 
between the number of MANF-expressing beta-cells and beta-cell mass and 
consequently with blood glucose levels in individual mice demonstrating the 
significance of MANF expression for maintaining  the beta-cell mass. 
IV. Excision of MANF from beta-cells of adult mice by using tamoxifen-inducible MIP1-
CreERT::Manffl/fl mice led to the development of diabetes associated with decreased 
beta-cell mass caused by increased beta-cell apoptosis, possible de-differentiation of 
the beta-cell and reduced beta-cell proliferation. Thus, MANF expression in beta-cells 
is required for the maintenance and survival of adult beta-cells in mice. 
V. MANF-deficiency in pancreatic beta-cells and pituitary glands leads to ER stress and 
chronic UPR activation in vivo.  
VI. We identified that PI3K/Akt pathway is implicated in the MANF signaling. Our 
experiments show that MANF protein mitigates ER stress in Manf-/- islets in culture. 
Moreover, MANF-deficiency in cultured islets leads to the activation of pro-
inflammatory NF-κB, p38, JNK signaling cascades. These results might indicate that 
MANF could rescue beta-cells from apoptosis by relieving ER stress thus decreasing 
inflammatory signaling.  
VII. Recombinant MANF protein increased beta-cell proliferation in vitro in islets isolated 
from young and aged mice. Moreover, MANF protected mouse beta-cells from ER 
stress-induced beta-cell death triggered by thapsigargin and hyperglycemia-induced 
ER stress in vitro.  Thus, MANF showed mitogenic and protective effects for mouse 
beta-cells. 
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VIII. We also described a new fast and fully automated graphical software that assesses the 
areas of islets, beta-cells, alpha-cells and exocrine tissues of the pancreas based on the 
dCNN technique.  
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